naltrexone has been researched along with Alcohol Drinking in 433 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (2.08) | 18.7374 |
| 1990's | 66 (15.24) | 18.2507 |
| 2000's | 129 (29.79) | 29.6817 |
| 2010's | 180 (41.57) | 24.3611 |
| 2020's | 49 (11.32) | 2.80 |
| Authors | Studies |
|---|---|
| Azar, MR; Berzetei-Gurske, I; Cashman, JR; Ghirmai, S; Polgar, WE | 1 |
| Springer, SA | 1 |
| Green, R; Montoya, AK; Ray, LA | 1 |
| Kranzler, HR; Mann, K; Nakovics, H; Roos, CR; Votaw, VR; Witkiewitz, K | 1 |
| Corbin, WR; DeMartini, KS; Fucito, LM; Kranzler, HR; Leeman, RF; MacKinnon, DP; O'Malley, SS; Waddell, JT | 1 |
| Habu, H; Hashimoto, N; Kishi, Y; Matsuo, K; Okahisa, Y; Sakamoto, S; Takaki, M; Takao, S; Yamada, N | 1 |
| Addolorato, G; Antonelli, M; Sestito, L; Tarli, C | 1 |
| Gueorguieva, R; O'Malley, SS; Phan, H; Wallach, JD; Witkiewitz, K; Wu, R | 1 |
| Ali, A; Arenander, J; Batki, S; Coffin, P; Ikeda, J; Jain, J; Matheson, T; McLaughlin, M; Santos, GM; Vittinghoff, E; Walker, J | 1 |
| Mason, BJ | 1 |
| Coralic, Z; Montoy, JCC; Murphy, CE; Ramirez, B; Raven, MC; Wang, RC | 1 |
| Bain, PA; Busch, AB; Huskamp, HA; Hyland, CJ; McDowell, MJ | 1 |
| Avery, J | 1 |
| Enders, CK; Nieto, SJ; O'Malley, SS; Ray, LA; Witkiewitz, K | 1 |
| Chuan-Ya, L; Ruei-Yuan, H | 1 |
| Agabio, R; Minozzi, S; Rösner, S; Saulle, R | 1 |
| Cosgrove, KP; de Laat, B; Hoye, J; Key, J; Krishnan-Sarin, S; Morris, ED; Papademetris, X | 1 |
| Al Hamdan, F; Böttcher, M; Grählert, X; Klut, IM; O'Connor, S; Plawecki, MH; Sauer, C; Smolka, MN; Sommer, WH; Spreer, M; Zimmermann, US | 1 |
| Ipsarides, J | 1 |
| Bobashev, G; Coffey, CP; Edlund, MD; Jonas, DE; Kennedy, SM; Kuznacic, K; McPheeters, M; O'Connor, EA; Riley, S; Voisin, C | 1 |
| Kranzler, HR; Mann, K; Roos, CR; Witkiewitz, K | 1 |
| Kreek, MJ; Zhou, Y | 2 |
| Duprez, R; Hammas, K; Ioannidis, JPA; Laviolle, B; Naudet, F; Palpacuer, C | 1 |
| Cavallo, DA; Franco, N; Gueorguieva, R; Krishnan-Sarin, S; Krystal, JH; O'Malley, SS; Pittman, B; Shi, J; Tetrault, JM | 1 |
| Braillon, A; Naudet, F; Palpacuer, C | 1 |
| Bäckström, P; Carroll, FI; Eteläinen, T; Kiianmaa, K; Oinio, V; Piepponen, P; Raasmaja, A; Uhari-Väänänen, J | 1 |
| Alves, SS; Caldas, ED; de Oliveira, DGR; Mortari, MR; Nolli, LM; Pic-Taylor, A; von Zuben, MV | 1 |
| Brach, BS; Luderer, M; Meulien, D; Mueller, S; Schou, MB; Zhang, D | 1 |
| Caballeria, E; Gual, A; López-Pelayo, H; Mann, K; Van den Brink, W; Zuluaga, P | 1 |
| Hayashi, T; Higuchi, S; Miyata, H | 1 |
| Anton, RF; Arias, AJ; Feinn, R; Gelernter, J; Gueorguieva, R; Hartwell, EE; Hoffman, M; Kranzler, HR; Krystal, J; Morris, PE; Oslin, D; Petrakis, I; Schacht, JP | 1 |
| Dermody, SS; Hendershot, CS; Kennedy, JL; Stoner, SA; Wardell, JD; Zaso, MJ | 1 |
| Farrer, LA; Henderson, DC; Kranzler, HR; Lin, Y; Xu, H; Zhang, H | 1 |
| Anton, RF; Falk, DE; Hasin, DS; Heather, N; Kranzler, HR; Litten, RZ; Mann, KF; O'Malley, SS; Witkiewitz, K | 1 |
| Kuerbis, AN; Levak, S; Morgenstern, J | 1 |
| Tadori, Y | 1 |
| Higuchi, S; Meulien, D; Miyata, H; Murai, Y; Nakamura, I; Takahashi, M; Tsuneyoshi, K | 1 |
| Bardo, MT; Chandler, CM; Maggio, SE; Nixon, K; Peng, H | 1 |
| Bromley, E; Hurley, B; McCreary, M; Ober, AJ; Tarn, DM; Watkins, KE | 1 |
| de Laat, B; Froehlich, JC; Huang, Y; Krishnan-Sarin, S; Morris, ED; Nabulsi, N; O'Malley, SS | 1 |
| Fisher, H; Pajser, A; Pickens, CL | 1 |
| Brumback, B; Bryant, K; Bryant, V; Cook, RL; Hahn, JA; Richards, VL; Sajdeya, R; Villalba, K; Wang, Y | 1 |
| Grodin, EN; Ho, D; Ray, LA; Towns, B | 1 |
| Bäckström, P; Kiianmaa, K; Oinio, V; Piepponen, P; Raasmaja, A; Sundström, M; Uhari-Väänänen, J | 1 |
| Lesscher, HMB; Minnaard, AM; Ramakers, GMJ; Vanderschuren, LJMJ | 1 |
| Tamaki, K | 1 |
| Berquist, MD; Fantegrossi, WE | 1 |
| Bold, KW; Corbin, WR; DeMartini, KS; Fucito, LM; Kranzler, HR; Leeman, RF; Mann, K; O'Malley, SS; Roos, CR; Witkiewitz, K | 1 |
| Gasparyan, A; Manzanares, J; Navarrete, F | 1 |
| Montoy, JC; Murphy, CE; Raven, M; Wang, RC; Whittaker, E | 1 |
| Enders, C; Green, R; Grodin, EN; Hartwell, E; Ho, D; Leventhal, AM; Li, G; Lim, A; Meredith, L; Miotto, K; Nieto, SJ; Ray, LA; Shoptaw, S; Venegas, A | 1 |
| Bujarski, S; Du, H; Green, R; Grodin, EN; Nieto, SJ; Ray, LA; Roche, DJO | 1 |
| Burnette, EM; Green, R; Grodin, EN; Lim, AC; Miotto, K; Ray, LA | 1 |
| Anderson, ES; Chamberlin, M; D'Onofrio, G; Hawk, K; Herring, AA; McCormack, R; Ullal, M; Zuluaga, M | 1 |
| Altice, FL; Azar, MM; Barbour, R; Di Paola, A; Krishnan, A; Springer, SA | 1 |
| Brown, RA; Cioe, PA; Kahler, CW; Leggio, L; O'Malley, SS; Ramsey, SE; Spillane, NS; Tzilos, GK | 1 |
| Gajbhiye, SV; Petare, A; Potey, AV; Salve, B; Tripathi, RK | 1 |
| Gil, A; Guerri, C; Montesinos, J | 1 |
| Chiner, F; Ferreyra, A; Nizhnikov, ME; Pautassi, RM; Sciangula, M; Wille-Bille, A | 1 |
| Holtyn, AF; Kaminski, BJ; Weerts, EM | 1 |
| Henderson-Redmond, AN; Lowe, TE; Morgan, DJ; Tian, XB | 1 |
| Ericson, M; Lidö, HH; Söderpalm, B | 1 |
| Barrio, P; Gual, A; Guardia, J; Ortega, L; Roncero, C; Yuguero, L | 1 |
| Brumback, B; Chen, X; Cook, RL; Hahn, JA; Miguez, MJ; Wang, Y; Zhou, Z | 1 |
| Aballéa, S; Daeppen, JB; Laramée, P; Millier, A; Rahhali, N; Rehm, J; Toumi, M | 1 |
| Kreek, MJ; Low, MJ; Rubinstein, M; Zhou, Y | 2 |
| Heinz, A; Hoffmann, S; Leménager, T; Mann, K; Nakovics, H; Roos, CR; Witkiewitz, K | 1 |
| Cousins, SJ; Crèvecoeur-MacPhail, D; Denering, L; Kim, T; Rawson, RA | 1 |
| Dilley, JE; Froehlich, JC; Nicholson, ER | 1 |
| Bujarski, S; Ghahremani, D; Green, R; Hartwell, EE; Hutchison, K; Lim, AC; Miotto, K; Ray, LA; Roche, DJO; Rohrbaugh, T | 1 |
| Donoghue, K | 1 |
| Anton, RF; Book, SW; Hoffman, M; Latham, PK; Randall, PK; Schacht, JP; Voronin, KE | 1 |
| Crowley, R; Kreek, MJ; Prisinzano, T; Zhou, Y | 1 |
| Ingram, E; Leong, SH; Maisto, SA; McKay, JR; Oslin, DW; Possemato, K; Rotenberg, JR | 1 |
| Du, Y; Ehrich, E; O'Malley, SS; Silverman, BL; Todtenkopf, MS | 1 |
| Brown, ST; Bryant, KJ; Edelman, EJ; Fiellin, DA; Fiellin, LE; Hansen, N; Holt, SR; Justice, AC; Kyriakides, TC; Moore, BA; Virata, M | 1 |
| Baillie, A; Haber, PS; Kranzler, HR; Luquin, N; Morley, KC; Shanahan, M; Teesson, M; Trent, R | 1 |
| Martin-Fardon, R; Matzeu, A; Terenius, L | 1 |
| Bardo, MT; Bell, RL; Crooks, PA; Dwoskin, LP; Maggio, SE; Nixon, K; Prendergast, MA; Saunders, MA; Zheng, G | 1 |
| Cioe, PA; Kahler, CW; Lechner, WV; Sidhu, NK | 1 |
| Lim, AC; Ray, LA; Roche, DJO | 1 |
| Krystal, JH; Petrakis, IL; Yoon, G | 1 |
| Bujarski, S; Green, R; Lim, AC; Ray, LA; Venegas, A | 1 |
| Hauser, SR; Knight, CP; McBride, WJ; Pratt, LA; Rodd, ZA; Waeiss, RA | 1 |
| Blasey, C; Heifets, BD; Rodriguez, CI; Schatzberg, AF; Sudheimer, K; Williams, NR | 1 |
| Umhau, JC | 1 |
| Anton, RF; Falk, DE; Fertig, J; Hasin, DS; Johnson, B; Kranzler, HR; Litten, RZ; Mann, KF; Meulien, D; O'Malley, SS; Ryan, M; Slater, M; Witkiewitz, K | 1 |
| Cami-Kobeci, G; Czoty, PW; Davenport, AT; Epperly, PM; Flynn, SM; Husbands, SM; Ko, MC | 1 |
| Hayashi, T; Higuchi, S; Meulien, D; Miyata, H; Murai, Y; Sørensen, P; Takahashi, M; Tsuneyoshi, K | 1 |
| Brumback, B; Bryant, K; Cook, RL; Espinoza, L; Lewis, JE; Miguez, MJ; Quiros, C; Zhou, Z | 1 |
| Blanchard, A; Chun, T; Gwaltney, CJ; Justus, A; Miranda, R; Monti, PM; Ramirez, J; Ray, L; Reynolds, EK; Swift, RM; Tidey, J | 1 |
| Azogu, I; Tomie, A; Yu, L | 1 |
| Cannella, N; Ciccocioppo, R; Cippitelli, A; de Guglielmo, G; Demopulos, G; Gaitanaris, G; Heilig, M; Kallupi, M; Somaini, L; Stopponi, S; Ubaldi, M | 1 |
| Gual, A; He, Y; Mann, K; Torup, L; van den Brink, W | 1 |
| Anton, RF; Baker, NL; Bandyopadhyay, D; DeSantis, SM; Prisciandaro, JJ; Randall, PK | 1 |
| Manzanares, J; Navarrete, F; Rubio, G | 1 |
| O'Connor, PG; O'Malley, SS | 1 |
| Ahern, J; Kaskutas, LA; Lendle, S; Subbaraman, MS; van der Laan, M | 1 |
| Cao, D; King, A; Rueger, SY; Zhang, L | 1 |
| Aubin, HJ; Daeppen, JB | 1 |
| Anderson, RI; Morales, M; Spear, LP; Varlinskaya, EI | 1 |
| Froehlich, JC; Hausauer, BJ; Rasmussen, DD | 1 |
| Keating, GM | 1 |
| Haddouk, H; Hwa, LS; Kalinichev, M; Miczek, KA; Poli, S | 1 |
| Anton, RF | 1 |
| Johnson, BA; Lynch, WJ; Moore, CF; Protzuk, OA | 1 |
| Cano-Cebrián, MJ; Granero, L; Martí-Prats, L; Orrico, A; Polache, A; Zornoza, T | 1 |
| Spence, D | 1 |
| Batel, P; Chick, J; Gual, A; Kiefer, F; Sinclair, J; Sørensen, P | 1 |
| Braillon, A | 2 |
| McNulty, SJ; Williams, P | 1 |
| Anton, RF; Falk, DE; Johnson, BA; Kranzler, HR; Litten, RZ | 1 |
| Gual, A; Mann, K; Sørensen, P; Torup, L; van den Brink, W | 1 |
| Aubin, HJ; Gual, A; Mann, K; van den Brink, W | 1 |
| Balguerie, K; Coune, F; Jeanblanc, J; Jeanblanc, V; Legastelois, R; Naassila, M | 1 |
| Brody, A; Courtney, KE; Ghahremani, DG; London, ED; Miotto, K; Ray, LA | 1 |
| Bordner, KA; Carter, JM; Landin, JD; Nizhnikov, ME; Pautassi, RM; Spear, NE; Varlinskaya, EI; Werner, DF | 1 |
| Clifasefi, SL; Collins, SE; Duncan, MH; Jackson, TR; Joesch, J; Malone, DK; Merrill, JO; Ries, RK; Saxon, AJ; Smart, BF | 1 |
| Jeong, HJ; Jung, WY; Kim, JH; Kim, SG; Lee, JS; Yang, YH | 1 |
| Ciccocioppo, R; Economidou, D; Heilig, M; Kinoshita, H; Kuriyama, M; Roberto, M; Stopponi, S; Teshima, K; Weiss, F | 1 |
| Hayes, L; Hendrie, D; Hulse, G; Jeffrey, GP; Kelty, E; Kyle, S; Mukhtar, A; O'Neil, G | 1 |
| Liang, J; Olsen, RW | 1 |
| Corbin, WR; DeMartini, KS; Fucito, LM; Leeman, RF; Lejuez, CW; O'Malley, SS; Toll, BA | 1 |
| Berrios-Cárcamo, PA; Buscaglia, M; Bustamante, D; Herrera-Marschitz, M; Israel, Y; Karahanian, E; Morales, P; Quintanilla, ME; Rivera-Meza, M | 1 |
| Braciszewski, JM; Falk, D; Kranzler, HR; O'Malley, SS; Stout, RL; Subbaraman, MS | 1 |
| Barbosa, C; Brodtkorb, TH; Daeppen, JB; François, C; Knight, C; Laramée, P; Rahhali, N; Rehm, J; Toumi, M | 1 |
| Aballéa, S; Bineau, S; Chalem, Y; François, C; Laramée, P; Millier, A; Rahhali, N; Rehm, J; Toumi, M | 1 |
| DeBold, JF; Hwa, LS; Kayyali, T; Miczek, KA; Norman, KJ; Shimamoto, A; Valentino, RJ | 1 |
| Cao, D; Fridberg, DJ; Grant, JE; King, AC | 1 |
| Fucito, LM; Gueorguieva, R; Hoffmann, S; Mann, K; O'Connor, PG; O'Malley, SS; Weisner, C; Wu, R | 1 |
| Fredriksson, I; Jardemark, K; Jayaram-Lindström, N; Nylander, E; Nyström, E; Steensland, P; Wirf, M | 1 |
| Bilbao, A; Heilig, M; Malanga, CJ; Robinson, JE; Sommer, WH; Spanagel, R; Thorsell, A | 1 |
| Bendimerad, P; Blecha, L | 1 |
| Amato, RJ; Hulin, MW; Lawrence, MN; Weed, PF; Winsauer, PJ | 1 |
| Brown, SA; Kivlahan, DR; Longabaugh, R; Witkiewitz, K; Worley, MJ | 1 |
| Gual, A; Jensen, TJ; Mann, K; Strang, J; Sørensen, P; van den Brink, W | 1 |
| Corbin, WR; DeMartini, KS; Fucito, LM; Gueorguieva, R; Ikomi, J; Kranzler, HR; Leeman, RF; O'Malley, SS; Romano, DM; Sher, KJ; Toll, BA; Wu, R | 1 |
| Hester, RK | 1 |
| Berrettini, W; Gordon, AJ; Leong, SH; Lynch, KG; O'Brien, CP; Oslin, DW; Rukstalis, M | 1 |
| Lieb, M; Soyka, M | 1 |
| Aubin, HJ; Bladström, A; Chick, J; François, C; Nutt, DJ; Reimer, J; Torup, L | 1 |
| Morgan, MY; Pandor, A; Rawdin, A; Rice, P; Stevens, JW; Stevenson, M; Thompson, J | 1 |
| Frohe, T; Kirouac, M; Maisto, SA; McCallion, E; Vowles, KE; Witkiewitz, K | 1 |
| Berrettini, W | 1 |
| Bujarski, S; Green, R; Hartwell, E; Ray, LA; Roche, DJ | 1 |
| Belin, D; Bullmore, ET; Economidou, D; Everitt, BJ; García-Pardo, MP; Giuliano, C; Goodlett, CR; Robbins, TW | 1 |
| Aubin, HJ; Chalem, Y; François, C; Luquiens, A; Rahhali, N; Sørensen, P | 1 |
| Kahler, CW; Knopik, VS; Lechner, WV; Leventhal, AM; McGeary, JE; McKee, SA; Metrik, J; Rohsenow, DJ; Spillane, NS; Tidey, JW | 1 |
| Bullmore, ET; Maltby, K; Miller, SR; Mugnaini, M; Nathan, P; Ripley, TL; Sanchez-Roige, S; Stephens, DN; Wille, DR | 1 |
| Froehlich, JC; Kincaid, CL; Rasmussen, DD | 1 |
| Anderson, SM; Brunzell, DH; Shelton, KL; Stafford, AM | 1 |
| Baroni, S; Dell'Osso, L; Marazziti, D; Mucci, F; Mungai, F; Piccinni, A; Presta, S | 1 |
| Bruhn, C | 1 |
| Sivolap, YP | 1 |
| Franchitto, N; Nubukpo, P; Pélissier, F; Rougé Bugat, ME | 1 |
| Anton, RF; Fitzmaurice, GM; Griffin, ML; McHugh, RK; Weiss, RD | 1 |
| Friede, M; Schnitker, J; Soyka, M | 1 |
| Canals, S; Dudek, M; Hyytiä, P; Sommer, WH | 1 |
| Addolorato, G; Bernardi, M; Caputo, F; D'Amore, A; Domenicali, M; Maremmani, AG; Maremmani, I; Zoli, G | 1 |
| Bell, M; Brodtkorb, TH; Irving, AH; Laramée, P | 1 |
| Bühler, KM; Calleja-Conde, J; Echeverry-Alzate, V; Giné, E; Gual, A; López-Moreno, JA; Maldonado, R; Nadal, R; Rodríguez de Fonseca, F | 1 |
| Canals, S; Ciccocioppo, R; Cosa, A; Hyytiä, P; Moratal, D; Moreno, A; Pacheco-Torres, J; Sommer, WH | 1 |
| Aballéa, S; Chalem, Y; Cristeau, O; François, C; Laramée, P; Millier, A; Rahhali, N; Rehm, J; Toumi, M | 1 |
| Hendershot, CS; Rehm, J; Samokhvalov, AV; Wardell, JD | 1 |
| Dilley, JE; Filosa, NJ; Fischer, SM; Froehlich, JC; Nicholson, ER; Rademacher, LC; Smith, TN | 2 |
| Aballéa, S; Brodtkorb, TH; Cristeau, O; Laramée, P; Millier, A; Montgomery, S; Rahhali, N; Rehm, J; Steeves, S; Toumi, M | 1 |
| Mann, K; Roos, CR; Witkiewitz, K | 1 |
| Boussageon, R; Laviolle, B; Naudet, F; Palpacuer, C | 1 |
| Bold, KW; Corbin, WR; DeMartini, KS; Fucito, LM; Kranzler, HR; Leeman, RF; O'Malley, SS | 2 |
| Canidate, SS; Carnaby, GD; Cook, CL; Cook, RL | 1 |
| Ben, K; Crowley, RS; Kreek, MJ; Prisinzano, TE; Zhou, Y | 1 |
| Di Giannantonio, M; Di Nicola, M; Janiri, L; Martinotti, G | 1 |
| Dackis, C; Dundon, W; Gariti, P; Gelfand, L; Kampman, KM; Lynch, KG; O'Brien, CP; Oslin, DW; Pettinati, HM; Ten Have, T; Volpicelli, JR; Wortman, S | 1 |
| Gilpin, NW; Koob, GF; Richardson, HN | 1 |
| Cui, CL; Guo, CY; Han, JS; Lee, DY; Lukas, SE; Ma, YY; Overstreet, DH | 1 |
| Abernathy, KE; Bartlett, SE; Chandler, LJ; Medina, B; Simms, JA; Steensland, P; Wise, R | 1 |
| Barrios De Tomasi, E; Juárez, J | 1 |
| Batki, SL; Dimmock, JA; Leontieva, L; Ploutz-Snyder, R | 1 |
| Schimmel, JS; Williams, KL | 1 |
| Alexander, M; Bohn, MJ; Forman, R; Illeperuma, A; Lapham, S | 1 |
| Cooney, NL; Krishnan-Sarin, S; Leeman, RF; Makuch, RW; McKee, SA; Meandzija, B; O'Malley, SS; Wu, R | 1 |
| Adedoyin, A; Akala, EO; Wang, H | 1 |
| McKee, SA | 1 |
| Bergren, LJ; Chen, KS; Fields, HL; Mitchell, JM; Rowbotham, MC | 1 |
| Gastfriend, DR; Kranzler, HR; Montejano, L; Stephenson, JJ; Wang, S | 1 |
| Hyytiä, P; Kemppainen, H; Kiianmaa, K | 1 |
| Rosenbloom, DL | 1 |
| Dong, Q; Gastfriend, DR; Kranzler, HR; O'Malley, SS; Pettinati, HM | 1 |
| Garbutt, JC | 2 |
| Czachowski, CL; Delory, MJ | 1 |
| Broadbridge, CL; Williams, KL | 1 |
| Cao, D; King, A; Vanier, C; Wilcox, T | 1 |
| Kenna, GA; Leggio, L; Ray, LA; Swift, RM | 1 |
| Arias, A; Armeli, S; Chan, G; Covault, J; Kranzler, HR; Oncken, C; Tennen, H | 1 |
| Ehlers, CL; Walker, BM | 1 |
| Davidson, D; Gulliver, SB; Longabaugh, R; Wirtz, PW | 1 |
| Nizhnikov, ME; Pautassi, RM; Spear, NE; Truxell, E | 1 |
| Ferraro Iii, FM; Hill, KG; Kiefer, SW; Sable, HJ | 1 |
| Couper, D; Donovan, D; Gueorguieva, R; Krystal, JH; O'Malley, SS; Rounsaville, BJ; Wu, R | 2 |
| Miller, GM; Platt, DM; Rüedi-Bettschen, D; Vallender, EJ | 1 |
| Baek, MN; Chai, YG; Choi, IG; Choi, MR; Chung, MK; Halder, D; Jung, KH; Jung, MH; Lee, BC; Lee, BH; Oh, DY | 1 |
| DiRocco, D; Gourevitch, MN; Grossman, E; Hanley, K; Lee, JD; Rotrosen, J; Stevens, D; Truncali, A | 1 |
| Bristow, RE; Grahame, NJ; Heighton, ME; Oberlin, BG | 1 |
| Ashenhurst, JR; Hutchison, KE; Morrow, AL; Ray, LA | 1 |
| Brissett, DI; van Rijn, RM; Whistler, JL | 1 |
| Bian, W; Cheng, Y; Li, J; Liu, X; Ye, JH; Zhang, C | 1 |
| Falk, D; Fertig, J; Johnson, B; Litten, RZ; Liu, L; Mattson, M; Ryan, M; Stout, R; Wang, XQ | 1 |
| Finn, DA; Ford, MM; Fretwell, AM; Tanchuck, MA; Yoneyama, N | 1 |
| Rösner, S; Soyka, M | 1 |
| Longabaugh, R; O'Malley, SS; Wirtz, PW; Zywiak, WH | 1 |
| Alvarez, S; Bobes, J; Flórez, G; García-Portilla, P; Nogueiras, L; Saiz, PA | 1 |
| Baek, MN; Chai, YG; Choi, IG; Choi, MR; Das, ND; Halder, D; Jung, KH; Oh, DY; Yu, J | 1 |
| Capone, C; Kahler, CW; O'Malley, SS; Swift, RM | 1 |
| Bowen, S; Donovan, DM; Witkiewitz, K | 1 |
| Gastfriend, DR | 1 |
| Benkelfat, C; Cox, SM; Gianoulakis, C; Leyton, M; Palmour, RM; Pihl, RO; Setiawan, E | 1 |
| Anton, RF; Baros, AM; Latham, PK; Myrick, H; Randall, PK; Waid, LR; Wright, TM | 1 |
| Gorelick, DA; Mannelli, P; Patkar, AA; Peindl, K; Tharwani, HM; Wu, LT | 1 |
| Altamirano, LJ; Boettiger, CA; D'Esposito, M; Fields, HL | 1 |
| Battisti, JJ; Forman, R; Gastfriend, DR; Pettinati, HM; Schweizer, E; Silverman, BL | 1 |
| Boudriau, S; Ciric, S; Johnson, FK; Kisicki, J; Stauffer, J | 1 |
| Daoura, L; Nylander, I | 1 |
| Finigan, MW; Parks, J; Perkins, T; Stringer, M; Zold-Kilbourn, P | 1 |
| Lapham, SC; McMillan, GP | 1 |
| Kemppainen, H; Kiianmaa, K; Raivio, N; Suo-Yrjo, V | 1 |
| Bell, RL; Dhaher, R; Hauser, SR; McBride, WJ; McKinzie, DL; Rodd, ZA; Toalston, JE | 1 |
| Bidlack, JM; Dean, RL; Deaver, DR; Eyerman, D; Todtenkopf, MS; Turncliff, RZ | 1 |
| Fabio, MC; Nizhnikov, ME; Pautassi, RM; Spear, NE | 1 |
| Aragon, CM; Baliño, P; Pastor, R; Tarragón, E | 1 |
| Maruotti, A; Rocci, R | 1 |
| Chambers, RA; Davidson, D; Kalapatapu, RK; Kruse, MI; Mehdiyoun, N; Radnovich, AJ | 1 |
| Bujarski, S; MacKillop, J; Ray, LA | 1 |
| Duke, AN; Kaminski, BJ; Weerts, EM | 1 |
| Bartlett, SE; Feduccia, AA; Li, R; Mill, D; Nielsen, CK; Santos, N; Simms, JA; Yi, H | 1 |
| Anton, RF; Myrick, H; Randall, PK; Tiffany, A; Voronin, KK | 1 |
| Bandyopadhyay, D; DeSantis, SM; Prisciandaro, JJ | 1 |
| Bühler, KM; Echeverry-Alzate, V; Giné, E; Gorriti, MÁ; Huertas, E; López-Moreno, JA; Olmos, P; Rodríguez de Fonseca, F; Santos, Á; Tuda-Arízcun, M | 1 |
| Armeli, S; Covault, J; Kranzler, HR; Tennen, H | 1 |
| Carlsson, A; Feltmann, K; Franck, J; Fredriksson, I; Holst, S; Schilström, B; Steensland, P | 1 |
| Oberpichler-Schwenk, H | 1 |
| Gourevitch, MN; Grossman, E; Huben, L; Lee, JD; Manseau, M; McNeely, J; Rotrosen, J; Stevens, D | 1 |
| Anton, RF; Henderson, S; Li, X; Myrick, H; Randall, PK; Schacht, JP; Voronin, KE | 1 |
| Cottone, P; Kwak, J; Rice, KC; Sabino, V | 1 |
| Bujarski, S; Lunny, K; O'Malley, SS; Ray, LA | 1 |
| Bladström, A; Gual, A; Mann, K; Torup, L; van den Brink, W | 1 |
| Hay, RA; Hodge, CW; Jennings, JH; Robinson, DL; Zitzman, DL | 1 |
| Lee, YS; Na, C | 1 |
| Ciccocioppo, R; Martin-Fardon, R; Weiss, F | 1 |
| Alamo, C; Jimenez-Arriero, MA; Lopez-Muñoz, F; Manzanares, J; Palomo, T; Ponce, G; Rubio, G | 1 |
| King, AC | 1 |
| Mackler, SA; O'Brien, CP; Sengpiel, T; Stromberg, MF; Vogel, WH; Volpicelli, JR | 1 |
| Anton, RF; Drobes, DJ; Thomas, SE; Voronin, K | 2 |
| Addolorato, G; Bernardi, M; Caputo, F; del RE, A; Domenicali, M; Gasbarrini, G; Greco, G; Lorenzini, F; Stefanini, GF | 1 |
| Liljequist, S; Pickering, C | 1 |
| Heyser, CJ; Koob, GF; Moc, K | 1 |
| Armeli, S; Blomqvist, O; Feinn, R; Kranzler, HR; Oncken, C; Petry, N; Tennen, H | 1 |
| Cramer, J; Feinn, R; Kranzler, HR; Tennen, H | 1 |
| Gallate, JE; Mallet, PE; McGregor, IS | 1 |
| Han, BD; Kim, MJ; Kim, SG; Park, JM; Stromberg, MF | 1 |
| Anton, RF; Drobes, DJ; Durazo-Avizu, R; Moak, D; Voronin, K | 1 |
| Broadbear, JH; Williams, KL; Woods, JH | 1 |
| Hensley, K; Holloway, F; Mhatre, M; Pruthi, R | 1 |
| Abu-Hasaballah, K; Feinn, R; Kranzler, HR; Tennen, H; Young, K | 1 |
| Gonzalvo Cirac, B; Guardia Serecigni, J; Martí Gil, A; Segura García, L; Suárez González, A; Tejero Pociello, A; Trujols Albet, J | 1 |
| Stromberg, MF | 1 |
| O'Brien, CP | 1 |
| Lee, TH | 1 |
| Coonfield, DL; Ferraro, FM; Kiefer, SW; Sinclair, JD | 1 |
| Kenna, GA; McGeary, JE; Swift, RM | 1 |
| Carai, MA; Colombo, G; Gessa, GL; Serra, S; Vacca, G | 1 |
| Bares, R; Braus, DF; Braus, DH; Croissant, B; Dohmen, BM; Heinz, A; Hermann, D; Machulla, HJ; Mann, K; Mundle, G; Reimold, M; Schumann, G; Wrase, J | 1 |
| Cello, R; Galloway, GP; Koch, M; Smith, DE | 1 |
| Feinn, R; Kranzler, HR | 1 |
| Fields, HL; Liang, MT; Mitchell, JM | 1 |
| Cucculelli, M; Massi, M; Mattioli, L; Perfumi, M | 1 |
| Belger, A; Brush, L; D'Souza, DC; Gueorguieva, R; Krystal, JH; Madonick, S; Perry, E; Wray, Y | 1 |
| Aicardi, G; Burattini, C; Gill, TM; Janak, PH | 1 |
| Ciccocioppo, R; Economidou, D; Heilig, M; Massi, M; Rimondini, R; Sommer, W | 1 |
| Armeli, S; Hernandez-Avila, CA; Kranzler, HR; Kuo, L; Song, C; Tennen, H | 1 |
| Coonfield, DL; Ferraro, FM; Hill, KG; Kiefer, SW | 1 |
| Armeli, S; Feinn, R; Kranzler, HR; Tennen, H | 1 |
| Escher, T; Mittleman, G | 1 |
| Balester-Mouret, S; Batel, P | 1 |
| Bakalkin, G; Kreek, MJ; Kuzmin, A; Liljequist, S | 1 |
| McGeary, JE; Miranda, R; Monti, PM; Rohsenow, DJ; Swift, R; Tidey, J | 1 |
| Czarnecka, E; Dyr, W; Gorska, D; Zalewska-Kaszubska, J | 2 |
| Cottone, P; Koob, GF; Lee, MJ; Rice, KC; Sabino, V; Steardo, L; Zorrilla, EP | 1 |
| Manzanares, J; Oliva, JM | 1 |
| Dayas, CV; Liu, X; Simms, JA; Weiss, F | 1 |
| Dackis, CA; Kampman, KM; O'Brien, CP; Oslin, DW; Pettinati, HM; Rabinowitz, AR; Wortman, SP | 1 |
| Lucchini, A; Manzato, E; Nava, F; Premi, S | 1 |
| Kordik, CP; Levin, ED; Overstreet, DH; Reitz, AB; Rezvani, AH; Rosenthal, DI; Vaidya, AH | 1 |
| Eliana, Bde T; Juárez, J | 1 |
| Bhayana, R; Gupta, T; Kamdar, NK; Miller, SA; Rhodes, JS; Syed, YM | 1 |
| Krishnan-Sarin, S; Krystal, JH; O'Malley, SS; Pittman, B; Shi, J | 1 |
| Cottone, P; Sabino, V; Schmidhammer, H; Steardo, L; Zorrilla, EP | 1 |
| Jimenez-Gomez, C; Shahan, TA | 1 |
| Capone, C; Farren, CK; Grilo, CM; McKee, SA; O'Malley, SS; Rounsaville, BJ; Sinha, R; Wu, R | 1 |
| Andreoli, M; Ashby, CR; Gardner, EL; Heidbreder, CA; Hutcheson, DM; Marcon, C | 1 |
| Higley, AE; Kiefer, SW | 1 |
| Kallio, A; Karhuvaara, S; Löyttyniemi, E; Mäkelä, R; Nurminen, T; Rosberg, M; Simojoki, K; Virta, A | 1 |
| Bridden, C; Cheng, DM; Edwards, EM; Egorova, VY; Krupitsky, EM; Raj, A; Samet, JH; Walley, AY; Woody, GE; Zvartau, EE | 1 |
| McGeary, JE; Miranda, R; Monti, PM; Rohsenow, DJ | 1 |
| Hutchison, KE; Ray, LA | 1 |
| Dong, Q; Garbutt, JC; Gastfriend, DR; Kranzler, HR; O'Malley, SS | 1 |
| Abrams, DB; Gwaltney, CJ; MacKillop, J; McGeary, JE; Miranda, R; Monti, PM; Paty, JA; Rohsenow, DJ; Shiffman, S; Swift, RM; Tidey, JW | 1 |
| Collins, J; Cramer, J; Gueorguieva, R; Krystal, JH; Rosenheck, R | 1 |
| Lehert, P; Leucht, S; Rösner, S; Soyka, M | 1 |
| Illeperuma, A; Lucey, MR; O'Brien, CP; Silverman, BL | 1 |
| Endo, T; Fujiwara, Y; Mizutani, R; Sanbe, A; Takagi, N; Takeo, S; Tanoue, A; Tsujimoto, G; Yamauchi, J | 1 |
| Kuzmin, A; Liljequist, S; Stenback, T | 1 |
| June, HL | 1 |
| Fogel, WA; Stasiak, A | 1 |
| Corbin, WR; Leeman, RF; Meandzija, B; O'Malley, SS; Palmer, RS; Romano, DM | 1 |
| Ho, AK; Rossi, N | 1 |
| Arndt, IC; Evans, B; Greenstein, RA; McLellan, AT; O'Brien, CP | 1 |
| Critcher, EC; Lin, CI; Myers, RD; Patel, J | 1 |
| Froehlich, JC; Jing, SL; Krishnan-Sarin, S; Kurtz, DL; Li, TK; Portoghese, PS; Zweifel, M | 1 |
| Froehlich, JC; Krishnan-Sarin, S; Li, TK; Portoghese, PS | 1 |
| Swift, RM | 1 |
| Clay, KL; O'Brien, CP; Volpicelli, JR; Watson, NT | 1 |
| Ulm, RR; Volpicelli, JR; Volpicelli, LA | 1 |
| Gianoulakis, C | 1 |
| King, AC; O'Brien, CP; Sherman, CE; Volpicelli, JR; Watson, NT | 1 |
| Froehlich, JC; Li, TK | 1 |
| Buongiorno, G; Hsuing, H; Kuznetsov, O; Swift, RM; Whelihan, W | 1 |
| Chow, S; Lê, AD; Poulos, CX; Quan, B | 1 |
| Jaffe, AJ; O'Malley, SS; Rode, S; Rounsaville, BJ | 1 |
| Chang, G; Jaffe, AJ; Meyer, RE; O'Malley, SS; Rode, S; Rounsaville, B; Schottenfeld, R | 1 |
| Anton, RF; Latham, PK; Moak, DH | 1 |
| Gardell, LR; Hubbell, CL; Reid, LD | 1 |
| Davidson, D; Fitz, E; Swift, R | 1 |
| Honkanen, A; Hyytiä, P; Korpi, ER; Sarviharju, M; Vilamo, L; Wegelius, K | 1 |
| Lankford, MF; Myers, RD | 1 |
| Chang, G; Jaffe, AJ; Meyer, RE; O'Malley, SS; Rounsaville, B; Schottenfeld, RS | 2 |
| Chattopadhyay, S; Gardell, LR; Hubbell, CL; Reid, LD | 1 |
| Le, AD; Sellers, EM | 1 |
| Grupp, LA; Harding, S; Szczepanska, R | 1 |
| Herz, A | 1 |
| Alterman, AI; Lifrak, PD; O'Brien, CP; Volpicelli, JR | 1 |
| Frazer, A; King, AC; O'Brien, CP; Volpicelli, JR | 1 |
| Farren, CK; O'Malley, S | 1 |
| Hill, KG; Kiefer, SW | 1 |
| Amit, Z; Davidson, D | 1 |
| Dorow, JD; Phillips, TJ; Wenger, CD | 1 |
| Alterman, AI; O'Brien, CP; Rhines, JS; Rhines, KC; Volpicelli, JR; Volpicelli, LA | 1 |
| Cramblett, MJ; de Wit, H; Doty, P; Kirk, JM | 1 |
| O'Brien, CP; Weinrieb, RM | 1 |
| Cavallaro, CA; Chattophadyay, S; Gardell, LR; Hubbell, CL; Reid, LD; Whalen, CA | 1 |
| Farren, CK; O'Connor, PG; O'Malley, SS; Rounsaville, BJ | 1 |
| Boedeker, KL; Gardell, LR; Hubbell, CL; Liakos, TM; Reid, LD | 1 |
| Froehlich, JC; Krishnan-Sarin, S; Li, XW; Portoghese, PS; Wand, GS | 1 |
| Honkanen, A; Hyytiä, P; Korpi, ER; Ovaska, T; Soini, SL | 1 |
| Boyle, AE; Johnson, BA; Macenski, MJ; Meisch, RA; Spiga, R; Stewart, RB | 1 |
| Casale, M; O'Brien, CP; Stromberg, MF; Volpicelli, JR; Volpicelli, L | 1 |
| Biggs, TA; Myers, RD | 1 |
| Badia-Elder, NE; Froehlich, JC; McCullough, DE; Portoghese, PS; Zink, RW | 1 |
| Hersh, D; Kranzler, HR; Van Kirk, JR | 1 |
| Pakarinen, ED; Williams, KL; Winger, G; Woods, JH | 1 |
| Williams, KL; Woods, JH | 2 |
| Cummings, R; Durr, LF; Grey, C; Johnson, A; June, HL; Lawrence, A; Mason, D; McCane, S; Ricks-Cord, A; Warren-Reese, C; Williams, LS | 1 |
| Kampman, KM; O'Brien, CP; Oslin, DW; Pettinati, HM; Volpicelli, JR; Wolf, AL | 1 |
| Bird, C; Davidson, D; Palfai, T; Swift, R | 1 |
| Katner, SN; Magalong, JG; Weiss, F | 1 |
| De Vries, TJ; Homberg, JR; Mulder, AH; Nestby, P; Schoffelmeer, AN; Vanderschuren, LJ; Wardeh, G | 1 |
| Cowen, MS; Jarrott, B; Lawrence, AJ; Rezvani, AH | 1 |
| Bienkowski, P; Koros, E; Kostowski, W | 1 |
| Pakarinen, ED; Williams, KL; Woods, JH | 1 |
| Cutler, RB; Mason, BJ; Ritvo, EC; Salvato, FR; Williams, LD | 1 |
| Farren, CK; O'Malley, SS | 1 |
| Farren, CK; Namkoong, K; O'Connor, PG; O'Malley, SS | 1 |
| Harding, S; Juzytsch, W; Lê, AD; Poulos, CX; Shaham, Y; Watchus, J | 1 |
| de Wit, H; Svenson, J; York, A | 1 |
| Anton, RF; Dias, JK; Latham, PK; Malcolm, RJ; Moak, DH; Waid, LR | 1 |
| Froehlich, JC; June, HL; Li, TK; McCane, SR; Portoghese, PS; Zink, RW | 1 |
| Clark, E; Hamedi, M; Janowsky, DS; Mason, GA; Overstreet, DH; Rezvani, AH; Yang, Y | 1 |
| Fiellin, DA; O'Connor, PG; Reid, MC | 1 |
| Cheskin, LJ; Eissenberg, T; McCaul, ME; Rohde, CA; Wand, GS | 1 |
| Anton, RF; Drobes, DJ | 1 |
| Ali, JA; Rush, CR | 1 |
| Armant, DR; Hannigan, JH | 1 |
| Koob, GF | 1 |
| de Wit, H | 1 |
| Lee, SM; McCaul, ME; Rohde, C; Wand, GS | 1 |
| Colby, SM; Eaton, CA; Gordon, A; Martin, RA; Monti, PM; Mueller, TI; Rohsenow, DJ; Swift, RM | 1 |
| O'Brien, CP; Rukstalis, MR; Stromberg, MF; Volpicelli, JR | 1 |
| Parkes, H; Sinclair, JD | 1 |
| Quintanilla, ME; Tampier, L | 1 |
| Kim, MJ; Kim, SG; Park, JM; Stromberg, MF; Volpicelli, JR | 1 |
| Froehlich, JC; Grahame, NJ; Low, MJ; Mosemiller, AK | 1 |
| Brené, S; Franck, J; Lindholm, S; Werme, M | 1 |
| Affleck, G; Armeli, S; Kranzler, HR; Tennen, H | 1 |
| Colby, SM; Hutchison, KE; Kaplan, GB; Monti, PM; Rohsenow, DJ; Swift, RM | 1 |
| Hyytiä, P; Kiianmaa, K | 1 |
| Henniger, MS; Hölter, SM; Lipkowski, AW; Spanagel, R | 1 |
| Ait-Daoud, N; Hargita, ID; Johnson, BA; Prihoda, TJ | 1 |
| Mackler, SA; O'Brien, CP; Stromberg, MF; Volpicelli, JR | 1 |
| Ait-Daoud, N; Javors, M; Johnson, BA; Roache, JD; Zanca, NA | 1 |
| Lee, SM; McCaul, ME; Rohde, CA; Stauffer, R; Wand, GS | 1 |
| Boedeker, KL; Douglass, AV; Hubbell, CL; Reid, LD; Reid, ML | 1 |
| Amit, Z; Babinska, I; Campisi, M; Goodwin, FL | 1 |
| Abrams, DB; Asher, MK; Brown, RA; Colby, SM; Gordon, A; Gulliver, SB; Monti, PM; Mueller, TI; Niaura, RS; Rohsenow, DJ; Swift, RM | 1 |
| Kane, EC; Williams, KL; Woods, JH | 1 |
| Farren, C; Kreek, MJ; Krishnan-Sarin, S; O'Malley, SS; Sinha, R | 1 |
| Mackler, SA; O'Brien, CP; Rukstalis, MR; Stromberg, MF; Volpicelli, JR | 1 |
| Coonfield, DL; Ferraro, FM; Hill, KG; Kaczmarek, HJ; Kiefer, SW | 2 |
| Geller, I; Hartmann, RJ; Ross, D | 1 |
| Chen, RC; Ho, AK | 1 |
| Alterman, AI; Hayashida, M; O'Brien, CP; Volpicelli, JR | 1 |
| Goosen, C; Kornet, M; Van Ree, JM | 2 |
| Grupp, LA; Lingham, T; Perlanski, E | 1 |
| Sinclair, JD | 1 |
| Linseman, MA | 1 |
| Allen, JI; DeMaster, EG; Go, VL; Ho, SB; Levine, AS; Morley, JE; Shafer, RB | 1 |
| Martinez, TT; Oster, L | 1 |
| Davis, MA; Olgin, JE; Volpicelli, JR | 1 |
42 review(s) available for naltrexone and Alcohol Drinking
| Article | Year |
|---|---|
Perspectives on the pharmacological management of alcohol use disorder: Are the approved medications effective?
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Disulfiram; Humans; Naltrexone | 2022 |
Looking Back, Looking Forward: Current Medications and Innovative Potential Medications to Treat Alcohol Use Disorder.
Topics: Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Alcoholism; Humans; Naltrexone; National Institute on Alcohol Abuse and Alcoholism (U.S.); National Institutes of Health (U.S.); United States | 2022 |
Integration of pharmacotherapy for alcohol use disorder treatment in primary care settings: A scoping review.
Topics: Acamprosate; Adolescent; Alcohol Drinking; Alcoholism; Disulfiram; Humans; Naltrexone; Primary Health Care; Randomized Controlled Trials as Topic; United States | 2023 |
Baclofen for alcohol use disorder.
Topics: Acamprosate; Adult; Alcohol Drinking; Alcoholism; Baclofen; Chronic Disease; Female; Humans; Male; Middle Aged; Naltrexone | 2023 |
Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Drug-Related Side Effects and Adverse Reactions; Humans; Naltrexone; Prospective Studies; Psychosocial Intervention; Quality of Life; United States | 2023 |
Safety of nalmefene for the treatment of alcohol use disorder: an update.
Topics: Alcohol Drinking; Alcohol-Related Disorders; Alcoholism; Drug Approval; Humans; Naltrexone; Narcotic Antagonists | 2020 |
Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder.
Topics: Adult; Alcohol Drinking; Alcoholism; Alleles; Female; Genotype; Humans; Male; Naltrexone; Narcotic Antagonists; Polymorphism, Single Nucleotide; Randomized Controlled Trials as Topic; Receptors, Opioid, mu; Recurrence | 2020 |
[Pharmacological profile and clinical findings of nalmefene (Selincro
Topics: Alcohol Drinking; Alcoholism; Animals; Clinical Trials, Phase III as Topic; Humans; Japan; Multicenter Studies as Topic; Naltrexone; Randomized Controlled Trials as Topic; Rats; Receptors, Opioid, kappa; Receptors, Opioid, mu | 2020 |
Effect of extended-release naltrexone on alcohol consumption: a systematic review and meta-analysis.
Topics: Adult; Alcohol Drinking; Alcoholism; Humans; Naltrexone; Narcotic Antagonists; Time Factors; Treatment Outcome | 2022 |
A meta-regression of methodological features that predict the effects of medications on the subjective response to alcohol.
Topics: Adolescent; Adult; Affect; Aged; Aged, 80 and over; Alcohol Drinking; Alcoholism; Behavior; Breath Tests; Child; Craving; Dose-Response Relationship, Drug; Ethanol; Humans; Hypnotics and Sedatives; Middle Aged; Naltrexone; Treatment Outcome; Young Adult | 2021 |
The Glycine Receptor-A Functionally Important Primary Brain Target of Ethanol.
Topics: Acamprosate; Alcohol Drinking; Animals; Brain; Dopamine; Ethanol; Humans; Naltrexone; Receptors, Glycine; Taurine | 2017 |
Medications for unhealthy alcohol use: across the spectrum.
Topics: Acamprosate; Alcohol Drinking; Alcoholism; Animals; Disulfiram; Dopamine Agents; Fructose; Humans; Naltrexone; Selective Serotonin Reuptake Inhibitors; Taurine; Topiramate | 2011 |
Emerging pharmacotherapies for alcohol dependence: a systematic review focusing on reduction in consumption.
Topics: Alcohol Abstinence; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Aripiprazole; Flupenthixol; Fluvoxamine; Fructose; Humans; Naltrexone; Piperazines; Psychotropic Drugs; Quinolones; Topiramate | 2013 |
Nalmefene: a review of its use in the treatment of alcohol dependence.
Topics: Alcohol Drinking; Alcoholism; Clinical Trials as Topic; Double-Blind Method; Humans; Internationality; Naltrexone; Randomized Controlled Trials as Topic | 2013 |
Bad medicine: nalmefene in alcohol misuse.
Topics: Alcohol Drinking; Alcoholism; Humans; Naltrexone; Narcotic Antagonists; Neuroprotective Agents | 2014 |
Alcohol use disorders and current pharmacological therapies: the role of GABA(A) receptors.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Benzodiazepines; Disulfiram; Ethanol; Fructose; Humans; Naltrexone; Narcotic Antagonists; Neuroprotective Agents; Plant Preparations; Receptors, GABA-A; Taurine; Topiramate | 2014 |
[Benefits in reducing alcohol consumption: how nalmefene can help].
Topics: Adolescent; Adult; Alcohol Drinking; Alcoholism; Behavior Therapy; Cause of Death; Europe; Female; Humans; Male; Middle Aged; Naltrexone; Risk Factors; Treatment Outcome; Young Adult | 2014 |
Safety and tolerability of as-needed nalmefene in the treatment of alcohol dependence: results from the Phase III clinical programme.
Topics: Adult; Alcohol Drinking; Alcoholism; Clinical Trials, Phase III as Topic; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Treatment Outcome | 2015 |
Recent Developments in Pharmacotherapy of Alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Anticonvulsants; Baclofen; Humans; Naltrexone; Narcotic Antagonists; Pharmacogenetics; Randomized Controlled Trials as Topic; Taurine; Varenicline | 2015 |
Nalmefene for Reducing Alcohol Consumption in People with Alcohol Dependence: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Topics: Adult; Alcohol Drinking; Alcoholism; Combined Modality Therapy; Cost-Benefit Analysis; Humans; Naltrexone; Narcotic Antagonists; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Social Support | 2015 |
Nalmefene: A Novel Drug for an Old Disorder.
Topics: Alcohol Drinking; Alcoholism; Animals; Humans; Naltrexone | 2015 |
Comparing Nalmefene and Naltrexone in Alcohol Dependence: Are there any Differences? Results from an Indirect Meta-Analysis.
Topics: Adult; Alcohol Drinking; Alcoholism; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Treatment Outcome | 2016 |
Effects of naltrexone on alcohol self-administration and craving: meta-analysis of human laboratory studies.
Topics: Alcohol Drinking; Alcoholism; Central Nervous System Depressants; Craving; Ethanol; Humans; Naltrexone; Narcotic Antagonists; Research Design; Self Administration | 2017 |
A Systematic Review of Naltrexone for Attenuating Alcohol Consumption in Women with Alcohol Use Disorders.
Topics: Alcohol Drinking; Alcohol-Related Disorders; Female; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Secondary Prevention; Treatment Outcome | 2017 |
Developing human laboratory models of smoking lapse behavior for medication screening.
Topics: Alcohol Drinking; Arousal; Bupropion; Cues; Drug Evaluation, Preclinical; Humans; Models, Psychological; Motivation; Naltrexone; Nicotine; Psychotropic Drugs; Secondary Prevention; Smoking; Smoking Cessation; Smoking Prevention; Social Environment; Social Facilitation; Tobacco Use Disorder | 2009 |
The state of pharmacotherapy for the treatment of alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Baclofen; Delayed-Action Preparations; Disulfiram; Fructose; Humans; Medication Adherence; Naltrexone; Taurine; Temperance; Topiramate | 2009 |
Efficacy and tolerability of naltrexone in the management of alcohol dependence.
Topics: Alcohol Deterrents; Alcohol Drinking; Alcoholism; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Naltrexone; Narcotic Antagonists; Nausea | 2010 |
Nalmefene for treatment of alcohol dependence.
Topics: Alcohol Drinking; Alcoholism; Animals; Clinical Trials as Topic; Humans; Naltrexone | 2010 |
Intramuscular extended-release naltrexone: current evidence.
Topics: Alcohol Drinking; Alcohol-Related Disorders; Alcoholism; Delayed-Action Preparations; Humans; Injections, Intramuscular; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2011 |
Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment, part 1.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Animals; Clinical Trials as Topic; Disulfiram; Excitatory Amino Acid Antagonists; Humans; Naltrexone; Narcotic Antagonists; Taurine | 2004 |
Does effect size in naltrexone trials for alcohol dependence differ for single-site vs. multi-center studies?
Topics: Alcohol Drinking; Alcoholism; Humans; Models, Statistical; Multicenter Studies as Topic; Naltrexone; Narcotic Antagonists; Outcome Assessment, Health Care; Placebos; Publishing; Randomized Controlled Trials as Topic; Recurrence; Regression Analysis; Research Design | 2005 |
The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking.
Topics: Adolescent; Adult; Aged; Alcohol Drinking; Alcoholism; Double-Blind Method; History, 20th Century; Humans; Middle Aged; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Recurrence; Research Design; Severity of Illness Index; Time Factors; Treatment Outcome | 2006 |
Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Humans; Middle Aged; Naltrexone; Narcotic Antagonists; Publication Bias; Secondary Prevention; Taurine | 2008 |
Effect of naltrexone on human alcohol consumption.
Topics: Alcohol Drinking; Alcoholism; Animals; Behavior, Animal; Humans; Naltrexone; Narcotic Antagonists; Opioid Peptides | 1995 |
Opiates and alcohol self-administration in animals.
Topics: Alcohol Drinking; Animals; Behavior, Animal; Ethanol; Humans; Naloxone; Naltrexone; Narcotic Antagonists; Narcotics; Rats; Receptors, Opioid; Reinforcement, Psychology; Self Administration | 1995 |
Endogenous opioids and excessive alcohol consumption.
Topics: Alcohol Drinking; Animals; Brain; Endorphins; Enkephalins; Ethanol; Hypothalamus; In Vitro Techniques; Naltrexone; Pituitary Gland; RNA; Substance-Related Disorders | 1993 |
Recent developments in alcoholism:opioid peptides.
Topics: Alcohol Drinking; Alcoholism; Animals; Brain; Clinical Trials as Topic; Endorphins; Humans; Naltrexone; Neurotransmitter Agents; Receptors, Opioid | 1993 |
Endogenous opioid systems and alcohol addiction.
Topics: Alcohol Drinking; Alcoholism; Animals; Ethanol; Humans; Mesencephalon; Naltrexone; Narcotic Antagonists; Narcotics; Receptors, Opioid | 1997 |
New therapies for alcohol problems: application to primary care.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Clinical Trials as Topic; Humans; Naltrexone; Narcotic Antagonists; Primary Health Care; Psychotherapy; Research Design; Taurine; United States | 2000 |
Alcohol in pregnancy and neonatal outcome.
Topics: Abortion, Spontaneous; Alcohol Drinking; Birth Weight; Developmental Disabilities; Female; Fetal Alcohol Spectrum Disorders; Gestational Age; Humans; Maternal Behavior; Naltrexone; Pregnancy; Pregnancy Outcome | 2000 |
Animal models of craving for ethanol.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Animals; Behavior, Addictive; Conditioning, Operant; Disease Models, Animal; Drug Tolerance; Motivation; Naltrexone; Narcotic Antagonists; Predictive Value of Tests; Rats; Reinforcement, Psychology; Reproducibility of Results; Substance Withdrawal Syndrome; Taurine | 2000 |
Laboratory-based assessment of alcohol craving in social drinkers.
Topics: Alcohol Drinking; Behavior, Addictive; Choice Behavior; Humans; Naltrexone; Narcotic Antagonists; Self Disclosure | 2000 |
144 trial(s) available for naltrexone and Alcohol Drinking
| Article | Year |
|---|---|
Within- and between-person effects of naltrexone on the subjective response to alcohol and craving: A daily diary investigation.
Topics: Alcohol Drinking; Alcoholism; Craving; Double-Blind Method; Ethanol; Humans; Naltrexone; Narcotic Antagonists; Young Adult | 2022 |
Clinical moderators of response to nalmefene in a randomized-controlled trial for alcohol dependence: An exploratory analysis.
Topics: Alcohol Drinking; Alcoholism; Ethanol; Humans; Naltrexone; Narcotic Antagonists | 2022 |
Predictors of abstinence, no heavy drinking days, and a 2-level reduction in World Health Organization drinking levels during treatment for alcohol use disorder in the COMBINE study.
Topics: Adult; Alcohol Abstinence; Alcohol Drinking; Alcoholism; Humans; Naltrexone; Treatment Outcome; World Health Organization | 2022 |
Targeted Oral Naltrexone for Mild to Moderate Alcohol Use Disorder Among Sexual and Gender Minority Men: A Randomized Trial.
Topics: Alcohol Drinking; Alcoholism; Binge Drinking; Ethanol; Humans; Male; Naltrexone; Sexual and Gender Minorities | 2022 |
Combination treatment with varenicline and naltrexone reduces World Health Organization risk drinking levels.
Topics: Alcohol Drinking; Alcoholism; Double-Blind Method; Humans; Naltrexone; Treatment Outcome; Varenicline; World Health Organization | 2022 |
Using naltrexone to validate a human laboratory test system to screen new medications for alcoholism (TESMA)- a randomized clinical trial.
Topics: Alcohol Drinking; Alcoholism; Ethanol; Humans; Naltrexone; Narcotic Antagonists | 2023 |
Advancing Precision Medicine for Alcohol Use Disorder: Replication and Extension of Reward Drinking as a Predictor of Naltrexone Response.
Topics: Alcohol Deterrents; Alcohol Drinking; Alcoholism; Female; Humans; Male; Middle Aged; Naltrexone; Precision Medicine; Reward; Treatment Outcome | 2019 |
Influence of combined treatment with naltrexone and memantine on alcohol drinking behaviors: a phase II randomized crossover trial.
Topics: Adult; Alcohol Drinking; Cross-Over Studies; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Female; Humans; Male; Memantine; Naltrexone; Narcotic Antagonists; Young Adult | 2020 |
Open-label Study with Nalmefene as Needed Use in Alcohol-Dependent Patients with Evidence of Elevated Liver Stiffness and/or Hepatic Steatosis.
Topics: Alcohol Drinking; Alcoholism; Elasticity; Elasticity Imaging Techniques; Fatty Liver; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Treatment Outcome | 2020 |
An analysis of the effect of mu-opioid receptor gene (OPRM1) promoter region DNA methylation on the response of naltrexone treatment of alcohol dependence.
Topics: Adult; Age Factors; Alcohol Abstinence; Alcohol Drinking; Alcoholism; DNA Methylation; Double-Blind Method; Humans; Middle Aged; Naltrexone; Narcotic Antagonists; Pharmacogenetics; Pharmacogenomic Variants; Promoter Regions, Genetic; Receptors, Opioid, mu; Recurrence; Time Factors; Treatment Outcome; United States | 2020 |
World Health Organization risk drinking level reductions are associated with improved functioning and are sustained among patients with mild, moderate and severe alcohol dependence in clinical trials in the United States and United Kingdom.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Alcoholism; Behavior Therapy; Female; Health Surveys; Humans; Male; Mental Health; Middle Aged; Motivational Interviewing; Naltrexone; Risk; Treatment Outcome; United Kingdom; United States; World Health Organization | 2020 |
Drink goal difficulty effect on outcomes in moderation-based alcohol treatment for sexual minority men.
Topics: Alcohol Drinking; Alcoholism; Goals; Humans; Male; Naltrexone; Sexual and Gender Minorities; Treatment Outcome | 2020 |
Long-term safety and efficacy of nalmefene in Japanese patients with alcohol dependence.
Topics: Adult; Alcohol Drinking; Alcoholism; Double-Blind Method; Female; Humans; Japan; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Outcome Assessment, Health Care; Time Factors | 2020 |
Secondary Analysis of a Randomized Clinical Trial of Naltrexone Among Women Living With HIV: Correlations Between Reductions in Self-Reported Alcohol Use and Changes in Phosphatidylethanol.
Topics: Adult; Alcohol Deterrents; Alcohol Drinking; Female; Florida; Glycerophospholipids; HIV Infections; Humans; Middle Aged; Naltrexone; Self Report | 2021 |
A novel human laboratory model for screening medications for alcohol use disorder.
Topics: Alcohol Drinking; Alcoholism; Humans; Laboratories; Naltrexone; Varenicline | 2020 |
Reward drinking and naltrexone treatment response among young adult heavy drinkers.
Topics: Adolescent; Adult; Alcohol Drinking; Alcoholism; Blood Alcohol Content; Female; Humans; Male; Naltrexone; Reward; Young Adult | 2021 |
Efficacy of Combining Varenicline and Naltrexone for Smoking Cessation and Drinking Reduction: A Randomized Clinical Trial.
Topics: Adult; Alcohol Deterrents; Alcohol Drinking; Cholinergic Agonists; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Smoking Cessation; Smoking Cessation Agents; Varenicline | 2021 |
Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community.
Topics: Adult; Alcohol Drinking; Delayed-Action Preparations; Double-Blind Method; Female; HIV Infections; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Prisoners; Treatment Outcome; Young Adult | 2017 |
A Double-Blind Randomized Placebo-Controlled Trial of Oral Naltrexone for Heavy-Drinking Smokers Seeking Smoking Cessation Treatment.
Topics: Administration, Oral; Adult; Alcohol Drinking; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Acceptance of Health Care; Smoking; Smoking Cessation; Tobacco Use Cessation Devices; Treatment Outcome | 2017 |
Who Receives Nalmefene and How Does It Work in the Real World? A Single-Arm, Phase IV Study of Nalmefene in Alcohol Dependent Outpatients: Baseline and 1-Month Results.
Topics: Adult; Alcohol Drinking; Alcoholism; Ambulatory Care; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Outpatients; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2018 |
Phosphatidylethanol in Comparison to Self-Reported Alcohol Consumption Among HIV-Infected Women in a Randomized Controlled Trial of Naltrexone for Reducing Hazardous Drinking.
Topics: Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Biomarkers; Female; Glycerophospholipids; HIV Infections; Humans; Middle Aged; Naltrexone; Self Report | 2018 |
Precision Medicine in Alcohol Dependence: A Controlled Trial Testing Pharmacotherapy Response Among Reward and Relief Drinking Phenotypes.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Phenotype; Precision Medicine; Reward; Treatment Outcome | 2018 |
Pharmacogenetic Effects of Naltrexone in Individuals of East Asian Descent: Human Laboratory Findings from a Randomized Trial.
Topics: Adult; Alcohol Deterrents; Alcohol Drinking; Asian People; Central Nervous System Depressants; Craving; Double-Blind Method; Ethanol; Female; Humans; Male; Naltrexone; Pharmacogenomic Testing; Polymorphism, Single Nucleotide; Receptors, Opioid, mu; Self Administration; Young Adult | 2018 |
Nicotine-Use/Smoking Is Associated with the Efficacy of Naltrexone in the Treatment of Alcohol Dependence.
Topics: Adolescent; Adult; Aged; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Biomarkers; Double-Blind Method; Drug Interactions; Female; Humans; Male; Middle Aged; Naltrexone; Nicotine; Sialoglycoproteins; Smoking; Transferrin; Treatment Outcome; Young Adult | 2018 |
Post-intervention Durability of Alcohol Care Management: 1-Year Follow-up of a Randomized Controlled Trial.
Topics: Adult; Aged; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Disease Management; Female; Follow-Up Studies; Humans; Male; Middle Aged; Naltrexone; Primary Health Care; Single-Blind Method | 2018 |
Effects of the Opioid System Modulator, Samidorphan, on Measures of Alcohol Consumption and Patient-Reported Outcomes in Adults with Alcohol Dependence.
Topics: Adult; Alcohol Drinking; Alcoholism; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Reported Outcome Measures; Receptors, Opioid, mu; Treatment Outcome | 2018 |
Efficacy of Extended-Release Naltrexone on HIV-Related and Drinking Outcomes Among HIV-Positive Patients: A Randomized-Controlled Trial.
Topics: Adult; Alcohol Drinking; Alcoholism; Anti-Retroviral Agents; CD4 Lymphocyte Count; Counseling; Delayed-Action Preparations; Double-Blind Method; Female; HIV; HIV Infections; Humans; Injections, Intramuscular; Male; Medication Adherence; Middle Aged; Naltrexone; Narcotic Antagonists; Treatment Outcome | 2019 |
Topiramate versus naltrexone for alcohol use disorder: study protocol for a genotype-stratified, double-blind randomised controlled trial (TOP study).
Topics: Adolescent; Adult; Aged; Alcohol Abstinence; Alcohol Drinking; Alcoholism; Clinical Protocols; Double-Blind Method; Excitatory Amino Acid Antagonists; Female; Gene Frequency; Homozygote; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; New South Wales; Pharmacogenomic Variants; Prospective Studies; Receptors, Kainic Acid; Receptors, Opioid, mu; Recurrence; Research Design; Time Factors; Topiramate; Treatment Outcome; Young Adult | 2018 |
Effects of time-varying changes in tobacco and alcohol use on depressive symptoms following pharmaco-behavioral treatment for smoking and heavy drinking.
Topics: Adult; Alcohol Deterrents; Alcohol Drinking; Behavior Therapy; Depression; Female; Humans; Male; Middle Aged; Naltrexone; Smoking Cessation; Time Factors; Tobacco Smoking; Tobacco Use Disorder | 2019 |
Association of Combined Naltrexone and Ketamine With Depressive Symptoms in a Case series of Patients With Depression and Alcohol Use Disorder.
Topics: Adult; Alcohol Drinking; Alcoholism; Craving; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Ketamine; Male; Middle Aged; Naltrexone; Pilot Projects | 2019 |
Naltrexone and alcohol effects on craving for cigarettes in heavy drinking smokers.
Topics: Adult; Alcohol Drinking; Alcoholism; Breath Tests; Craving; Double-Blind Method; Drug Interactions; Ethanol; Female; Humans; Male; Naltrexone; Smokers; Smoking; Smoking Cessation; Tobacco Products; Young Adult | 2019 |
Evaluation of Drinking Risk Levels as Outcomes in Alcohol Pharmacotherapy Trials: A Secondary Analysis of 3 Randomized Clinical Trials.
Topics: Adult; Alcohol Abstinence; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Female; Humans; Male; Middle Aged; Naltrexone; Risk Assessment; Topiramate; Varenicline | 2019 |
Nalmefene in alcohol-dependent patients with a high drinking risk: Randomized controlled trial.
Topics: Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Double-Blind Method; Endpoint Determination; Female; Humans; Male; Middle Aged; Naltrexone; Risk; Treatment Outcome | 2019 |
Reduction in Drinking was Associated With Improved Clinical Outcomes in Women With HIV Infection and Unhealthy Alcohol Use: Results From a Randomized Clinical Trial of Oral Naltrexone Versus Placebo.
Topics: Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Anti-Retroviral Agents; CD4 Lymphocyte Count; Female; HIV Infections; Humans; Middle Aged; Naltrexone; Treatment Outcome; Viral Load | 2019 |
Effects of naltrexone on adolescent alcohol cue reactivity and sensitivity: an initial randomized trial.
Topics: Adolescent; Alcohol Drinking; Craving; Cross-Over Studies; Cues; Double-Blind Method; Female; Humans; Male; Medication Adherence; Motivation; Naltrexone; Narcotic Antagonists; Treatment Outcome | 2014 |
A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence.
Topics: Adult; Alcohol Drinking; Alcoholism; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Treatment Outcome | 2013 |
Modeling longitudinal drinking data in clinical trials: an application to the COMBINE study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Cognitive Behavioral Therapy; Combined Modality Therapy; Data Interpretation, Statistical; Disease Progression; Female; Humans; Longitudinal Studies; Male; Models, Statistical; Naltrexone; Narcotic Antagonists; Poisson Distribution; Risk-Taking; Taurine; Temperance; Treatment Outcome | 2013 |
Cravings as a mediator and moderator of drinking outcomes in the COMBINE study.
Topics: Alcohol Abstinence; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior Therapy; Combined Modality Therapy; Humans; Naltrexone; Narcotic Antagonists; Surveys and Questionnaires; Treatment Outcome | 2013 |
Effects of the opioid receptor antagonist naltrexone on smoking and related behaviors in smokers preparing to quit: a randomized controlled trial.
Topics: Adult; Alcohol Drinking; Behavior, Addictive; Chicago; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Smoking; Smoking Cessation; Treatment Outcome | 2013 |
Can alcohol dependent patients adhere to an 'as-needed' medication regimen?
Topics: Adult; Alcohol Drinking; Alcoholism; Double-Blind Method; Female; Humans; Male; Medication Adherence; Middle Aged; Naltrexone; Narcotic Antagonists; Self Care; Treatment Outcome | 2014 |
Cumulative proportion of responders analysis (CPRA) as a tool to assess treatment outcome in alcohol clinical trials.
Topics: Alcohol Deterrents; Alcohol Drinking; Alcoholism; Double-Blind Method; Fructose; Humans; Naltrexone; Narcotic Antagonists; Topiramate; Treatment Outcome | 2014 |
Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: A 1-year, randomised controlled study.
Topics: Adult; Alcohol Drinking; Alcoholism; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Young Adult | 2014 |
Varenicline, low dose naltrexone, and their combination for heavy-drinking smokers: human laboratory findings.
Topics: Adult; Alcohol Drinking; Benzazepines; Craving; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Nicotinic Agonists; Quinoxalines; Smoking; Smoking Cessation; Varenicline; Young Adult | 2014 |
Harm reduction with pharmacotherapy for homeless people with alcohol dependence: protocol for a randomized controlled trial.
Topics: Adult; Aged; Alcohol Drinking; Alcoholism; Biomarkers; Counseling; Craving; Delayed-Action Preparations; Female; Harm Reduction; Health Services; Humans; Ill-Housed Persons; Male; Middle Aged; Motivation; Naltrexone; Narcotic Antagonists; Public Assistance; Quality of Life; Research Design | 2014 |
A new look at risk-taking: using a translational approach to examine risk-taking behavior on the balloon analogue risk task.
Topics: Adolescent; Adult; Alcohol Drinking; Analysis of Variance; Animals; Choice Behavior; Decision Making; Double-Blind Method; Female; Humans; Impulsive Behavior; Male; Naltrexone; Narcotic Antagonists; Prospective Studies; Psychiatric Status Rating Scales; Regression Analysis; Risk-Taking; Self Report; Young Adult | 2014 |
What happens when people discontinue taking medications? Lessons from COMBINE.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior Therapy; Combined Modality Therapy; Cross-Sectional Studies; Drug Therapy, Combination; Female; Humans; Longitudinal Studies; Male; Medication Adherence; Middle Aged; Naltrexone; Patient Dropouts; Recurrence; Taurine | 2014 |
The cost-effectiveness and public health benefit of nalmefene added to psychosocial support for the reduction of alcohol consumption in alcohol-dependent patients with high/very high drinking risk levels: a Markov model.
Topics: Alcohol Drinking; Alcoholism; Combined Modality Therapy; Cost-Benefit Analysis; Female; Humans; Male; Markov Chains; Middle Aged; Naltrexone; Public Health; Risk Assessment; Social Support | 2014 |
Naltrexone improves quit rates, attenuates smoking urge, and reduces alcohol use in heavy drinking smokers attempting to quit smoking.
Topics: Adult; Alcohol Abstinence; Alcohol Drinking; Dose-Response Relationship, Drug; Double-Blind Method; Drinking Behavior; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Prevalence; Smoking; Smoking Cessation; Smoking Prevention; Time Factors; Treatment Outcome | 2014 |
Social network moderators of naltrexone and behavioral treatment effects on heavy drinking in the COMBINE study.
Topics: Adult; Alcohol Drinking; Alcoholism; Behavior Therapy; Combined Modality Therapy; Craving; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Social Support; Treatment Outcome; Young Adult | 2015 |
Reduction of alcohol drinking in young adults by naltrexone: a double-blind, placebo-controlled, randomized clinical trial of efficacy and safety.
Topics: Adolescent; Alcohol Drinking; Alcoholism; Combined Modality Therapy; Dose-Response Relationship, Drug; Double-Blind Method; Ethanol; Female; Humans; Male; Motivational Interviewing; Naltrexone; Social Facilitation; Young Adult | 2015 |
Naltrexone vs Placebo for the Treatment of Alcohol Dependence: A Randomized Clinical Trial.
Topics: Adult; Alcohol Drinking; Alcoholism; Alleles; Asparagine; Aspartic Acid; Double-Blind Method; Drug Administration Schedule; Female; Genotype; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Odds Ratio; Polymorphism, Single Nucleotide; Recurrence; Treatment Outcome | 2015 |
Clinical relevance of as-needed treatment with nalmefene in alcohol-dependent patients.
Topics: Adult; Alcohol Drinking; Alcoholism; Double-Blind Method; Female; Harm Reduction; Humans; Logistic Models; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Treatment Outcome | 2015 |
Pain as a predictor of heavy drinking and any drinking lapses in the COMBINE study and the UK Alcohol Treatment Trial.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Behavior Therapy; Chronic Pain; Combined Modality Therapy; Female; Humans; Male; Naltrexone; Pain Measurement; Recurrence; Taurine; Treatment Outcome | 2015 |
Combined varenicline and naltrexone treatment reduces smoking topography intensity in heavy-drinking smokers.
Topics: Adult; Alcohol Drinking; Double-Blind Method; Female; Humans; Male; Naltrexone; Smoking; Smoking Cessation; Varenicline | 2015 |
Reward and relief dimensions of temptation to drink: construct validity and role in predicting differential benefit from acamprosate and naltrexone.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Reproducibility of Results; Reward; Taurine; Treatment Outcome | 2017 |
Daily relations among affect, urge, targeted naltrexone, and alcohol use in young adults.
Topics: Adolescent; Adult; Affect; Alcohol Drinking; Counseling; Cues; Double-Blind Method; Female; Humans; Male; Naltrexone; Young Adult | 2016 |
Urgency traits moderate daily relations between affect and drinking to intoxication among young adults.
Topics: Adolescent; Adult; Affect; Alcohol Drinking; Alcoholic Intoxication; Double-Blind Method; Female; Humans; Male; Motivation; Naltrexone; Young Adult | 2017 |
Aripiprazole in the treatment of patients with alcohol dependence: a double-blind, comparison trial vs. naltrexone.
Topics: Adult; Alcohol Drinking; Alcoholism; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Piperazines; Quinolones; Secondary Prevention; Substance Withdrawal Syndrome | 2009 |
A placebo-controlled randomized clinical trial of naltrexone in the context of different levels of psychosocial intervention.
Topics: Adult; Alcohol Drinking; Alcoholism; Cognitive Behavioral Therapy; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Compliance; Patient Participation; Primary Health Care; Treatment Outcome | 2008 |
Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation.
Topics: Adult; Alcohol Drinking; Alcoholism; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Naltrexone; Smoking; Smoking Cessation | 2009 |
Naltrexone aversion and treatment efficacy are greatest in humans and rats that actively consume high levels of alcohol.
Topics: Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholic Intoxication; Analysis of Variance; Animals; Cross-Over Studies; Double-Blind Method; Female; Humans; Linear Models; Male; Naltrexone; Rats; Young Adult | 2009 |
Behavioral consequences of repeated nicotine during adolescence in alcohol-preferring AA and alcohol-avoiding ANA rats.
Topics: Adult; Alcohol Drinking; Alcoholism; Delayed-Action Preparations; Employment; Ethnicity; Female; Health Status; Humans; Male; Mental Health; Middle Aged; Naltrexone; Narcotic Antagonists; Psychiatric Status Rating Scales; Quality of Life; Social Behavior; Social Support; Surveys and Questionnaires | 2009 |
Effect of extended-release naltrexone (XR-NTX) on quality of life in alcohol-dependent patients.
Topics: Adult; Alcohol Drinking; Alcoholism; Delayed-Action Preparations; Employment; Ethnicity; Female; Health Status; Humans; Male; Mental Health; Middle Aged; Naltrexone; Narcotic Antagonists; Psychiatric Status Rating Scales; Quality of Life; Social Behavior; Social Support; Surveys and Questionnaires | 2009 |
Naltrexone decreases heavy drinking rates in smoking cessation treatment: an exploratory study.
Topics: Adult; Alanine Transaminase; Alcohol Drinking; Aspartate Aminotransferases; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Liver; Male; Naltrexone; Narcotic Antagonists; Smoking; Smoking Cessation; Treatment Outcome | 2009 |
Blood glucose level, alcohol heavy drinking, and alcohol craving during treatment for alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) Study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior Therapy; Blood Glucose; Counseling; Female; Humans; Male; Middle Aged; Naltrexone; Obsessive-Compulsive Disorder; Psychiatric Status Rating Scales; Taurine | 2009 |
Targeted naltrexone for problem drinkers.
Topics: Adult; Alcohol Drinking; Alcoholism; Combined Modality Therapy; Counseling; Drug Administration Schedule; Female; Humans; Linear Models; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Compliance; Sex Factors; Time Factors; Treatment Outcome | 2009 |
Extended naltrexone and broad spectrum treatment or motivational enhancement therapy.
Topics: Adult; Alcohol Drinking; Alcoholism; Cognitive Behavioral Therapy; Combined Modality Therapy; Double-Blind Method; Female; Humans; Male; Middle Aged; Motivation; Naltrexone; Narcotic Antagonists; Temperance; Time Factors; Treatment Outcome | 2009 |
Naltrexone selectively elevates GABAergic neuroactive steroid levels in heavy drinkers with the Asp40 allele of the OPRM1 gene: a pilot investigation.
Topics: Adult; Alcohol Drinking; Alcoholism; Alleles; Amino Acid Substitution; Aspartic Acid; Double-Blind Method; Female; gamma-Aminobutyric Acid; Humans; Male; Naltrexone; Pilot Projects; Polymorphism, Single Nucleotide; Pregnanolone; Receptors, Opioid, mu; Young Adult | 2010 |
Network support as a prognostic indicator of drinking outcomes: the COMBINE Study.
Topics: Acamprosate; Adult; Alcohol Drinking; Alcoholism; Female; Humans; Male; Naltrexone; Prognosis; Social Support; Taurine; Temperance; Treatment Outcome | 2010 |
Topiramate for the treatment of alcohol dependence: comparison with naltrexone.
Topics: Alcohol Drinking; Alcoholism; Excitatory Amino Acid Agents; Female; Fructose; Humans; Male; Medication Adherence; Middle Aged; Naltrexone; Quality of Life; Time Factors; Topiramate; Treatment Outcome | 2011 |
Does family history of alcoholism moderate naltrexone's effects on alcohol use?
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior Therapy; Family; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Compliance; Placebos; Sex Characteristics; Substance-Related Disorders; Taurine; Treatment Outcome | 2011 |
Moderating effects of a craving intervention on the relation between negative mood and heavy drinking following treatment for alcohol dependence.
Topics: Acamprosate; Adult; Affect; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior Therapy; Combined Modality Therapy; Factor Analysis, Statistical; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Taurine; Treatment Outcome | 2011 |
The effect of naltrexone on alcohol's stimulant properties and self-administration behavior in social drinkers: influence of gender and genotype.
Topics: Adolescent; Adult; Alcohol Drinking; Cross-Over Studies; Double-Blind Method; Female; Genotype; Humans; Male; Middle Aged; Naltrexone; Receptors, Opioid, mu; Self Administration; Sex Characteristics; Young Adult | 2011 |
Gabapentin combined with naltrexone for the treatment of alcohol dependence.
Topics: Adult; Alcohol Drinking; Alcoholism; Amines; Cyclohexanecarboxylic Acids; Drug Administration Schedule; Drug Therapy, Combination; Female; Gabapentin; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Secondary Prevention; Substance Withdrawal Syndrome; Treatment Outcome | 2011 |
Problem drinking and low-dose naltrexone-assisted opioid detoxification.
Topics: Adult; Alcohol Drinking; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Severity of Illness Index; Substance Withdrawal Syndrome; Treatment Outcome; Young Adult | 2011 |
Interaction between family history of alcoholism and Locus of Control in the opioid regulation of impulsive responding under the influence of alcohol.
Topics: Adult; Alcohol Drinking; Alcoholism; Analgesics, Opioid; Choice Behavior; Decision Making; Ethanol; Female; Humans; Impulsive Behavior; Internal-External Control; Male; Motor Activity; Naltrexone; Pedigree | 2011 |
Efficacy of extended-release naltrexone in patients with relatively higher severity of alcohol dependence.
Topics: Adult; Alcohol Drinking; Alcoholism; Cognitive Behavioral Therapy; Delayed-Action Preparations; Disease Progression; Double-Blind Method; Female; Humans; Injections; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Compliance; Psychiatric Status Rating Scales; Temperance; Time Factors; Treatment Outcome | 2011 |
Effects of alcohol on the pharmacokinetics of morphine sulfate and naltrexone hydrochloride extended release capsules.
Topics: Adult; Alcohol Drinking; Analgesics, Opioid; Analysis of Variance; Area Under Curve; Capsules; Cross-Over Studies; Delayed-Action Preparations; Drug Combinations; Drug Interactions; Ethanol; Female; Humans; Male; Metabolic Clearance Rate; Models, Biological; Morphine; Naltrexone; Narcotic Antagonists; Young Adult | 2012 |
Baseline trajectories of heavy drinking and their effects on postrandomization drinking in the COMBINE Study: empirically derived predictors of drinking outcomes during treatment.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior Therapy; Combined Modality Therapy; Female; Humans; Male; Middle Aged; Naltrexone; Random Allocation; Taurine; Temperance; Treatment Outcome | 2012 |
Effects of alcohol availability, access to alcohol, and naltrexone on self-reported craving and patterns of drinking in response to an alcohol-cue availability procedure.
Topics: Adult; Alcohol Drinking; Alcoholism; Behavior, Addictive; Cues; Dose-Response Relationship, Drug; Double-Blind Method; Ethanol; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Self Report | 2012 |
Understanding naltrexone mechanism of action and pharmacogenetics in Asian Americans via behavioral economics: a preliminary study.
Topics: Adult; Alcohol Drinking; Asian; Behavior, Addictive; Double-Blind Method; Ethanol; Female; Genotype; Humans; Infusions, Intravenous; Male; Models, Economic; Naltrexone; Narcotic Antagonists; Receptors, Opioid, mu | 2012 |
Naltrexone modification of drinking effects in a subacute treatment and bar-lab paradigm: influence of OPRM1 and dopamine transporter (SLC6A3) genes.
Topics: Adult; Aged; Alcohol Drinking; Alcoholism; Dopamine Plasma Membrane Transport Proteins; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Receptors, Opioid, mu; Social Environment; Treatment Outcome; Young Adult | 2012 |
Simultaneous modeling of the impact of treatments on alcohol consumption and quality of life in the COMBINE study: a coupled hidden Markov analysis.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior Therapy; Combined Modality Therapy; Drug Therapy, Combination; Humans; Markov Chains; Naltrexone; Quality of Life; Taurine; Treatment Outcome | 2012 |
Variation in OPRM1 moderates the effect of desire to drink on subsequent drinking and its attenuation by naltrexone treatment.
Topics: Adolescent; Adult; Aged; Alcohol Drinking; Alcoholism; Alleles; Counseling; Data Interpretation, Statistical; Female; Genotype; Heterozygote; Humans; Male; Medical Records; Middle Aged; Motivation; Naltrexone; Narcotic Antagonists; Pharmacogenetics; Placebos; Polymorphism, Single Nucleotide; Precision Medicine; Receptors, Opioid, mu; Treatment Outcome; Young Adult | 2013 |
Extended-release naltrexone plus medical management alcohol treatment in primary care: findings at 15 months.
Topics: Adult; Alcohol Drinking; Alcoholism; Delayed-Action Preparations; Feasibility Studies; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Primary Health Care; Temperance; Time Factors | 2012 |
Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues.
Topics: Adult; Alcohol Drinking; Alcoholism; Cues; Dopamine Plasma Membrane Transport Proteins; Female; Genetic Variation; Humans; Magnetic Resonance Imaging; Male; Naltrexone; Narcotic Antagonists; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Protein Binding; Receptors, Opioid, mu; Tandem Repeat Sequences; Treatment Outcome; Young Adult | 2013 |
The effects of drinking goal on treatment outcome for alcoholism.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Cognitive Behavioral Therapy; Female; Goals; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Recurrence; Taurine; Treatment Outcome | 2013 |
Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene.
Topics: Alanine Transaminase; Alcohol Drinking; Alcoholism; Double-Blind Method; Drug Administration Schedule; Female; gamma-Glutamyltransferase; Humans; Liver; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Secondary Prevention | 2013 |
Alcohol urge and plasma beta-endorphin change after alcohol challenge with naltrexone pretreatment in social drinkers.
Topics: Adrenocorticotropic Hormone; Adult; Alcohol Drinking; Behavior, Addictive; beta-Endorphin; Cross-Over Studies; Double-Blind Method; Humans; Hydrocortisone; Male; Naltrexone | 2002 |
Naltrexone improves outcome of a controlled drinking program.
Topics: Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Treatment Outcome | 2002 |
Role of naltrexone in initial smoking cessation: preliminary findings.
Topics: Adult; Alcohol Drinking; Double-Blind Method; Humans; Middle Aged; Naltrexone; Smoking; Smoking Cessation | 2002 |
A clinical laboratory paradigm for evaluating medication effects on alcohol consumption: naltrexone and nalmefene.
Topics: Adult; Aged; Alcohol Drinking; Alcoholism; Analysis of Variance; Environment; Female; Humans; Male; Middle Aged; Naltrexone | 2003 |
Gamma-hydroxybutyric acid versus naltrexone in maintaining alcohol abstinence: an open randomized comparative study.
Topics: Alcohol Drinking; Alcoholism; Female; Humans; Hydroxybutyrates; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Temperance; Time Factors; Treatment Outcome | 2003 |
Targeted naltrexone for early problem drinkers.
Topics: Adult; Alcohol Drinking; Analysis of Variance; Chi-Square Distribution; Female; Humans; Linear Models; Male; Middle Aged; Naltrexone; Risk Factors | 2003 |
Measurement and prediction of medication compliance in problem drinkers.
Topics: Adult; Alcohol Drinking; Female; Humans; Male; Medical Records; Middle Aged; Naltrexone; Patient Compliance; Predictive Value of Tests; Statistics, Nonparametric | 2003 |
Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: temporal effects of drinking.
Topics: Adult; Aged; Alcohol Drinking; Alcoholism; Analysis of Variance; Case-Control Studies; Central Nervous System Depressants; Ethanol; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Time Factors | 2004 |
Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers.
Topics: Adult; Aged; Alcohol Drinking; Alcoholism; Analysis of Variance; Behavior, Addictive; Female; Humans; Male; Middle Aged; Naltrexone | 2004 |
Pharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: an open-label trial.
Topics: Adolescent; Adult; Aged; Alcohol Drinking; Alcoholism; Delayed-Action Preparations; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Compliance; Treatment Outcome | 2005 |
Potentiation of low dose ketamine effects by naltrexone: potential implications for the pharmacotherapy of alcoholism.
Topics: Adult; Affect; Alcohol Drinking; Alcoholism; Double-Blind Method; Drug Synergism; Ethanol; Female; Humans; Ketamine; Male; Naltrexone; Receptors, N-Methyl-D-Aspartate | 2006 |
Targeted versus daily naltrexone: secondary analysis of effects on average daily drinking.
Topics: Adolescent; Adult; Alcohol Drinking; Alcoholism; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Placebos; Sex Characteristics; Time Factors | 2006 |
The effects of naltrexone on alcohol consumption and affect reactivity to daily interpersonal events among heavy drinkers.
Topics: Adolescent; Adult; Affect; Alcohol Drinking; Female; Humans; Interpersonal Relations; Male; Middle Aged; Naltrexone; Regression Analysis; Reinforcement, Psychology | 2006 |
Genetic moderators of naltrexone's effects on alcohol cue reactivity.
Topics: Adolescent; Adult; Alcohol Drinking; Alcoholism; Analysis of Variance; Chi-Square Distribution; Cues; Ethanol; Female; Genetic Variation; Genotype; Humans; Male; Naltrexone; Receptors, Dopamine D4; Receptors, Opioid, mu | 2006 |
Comparing treatments of alcoholism on craving and biochemical measures of alcohol consumptionst.
Topics: Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Biomarkers; Disulfiram; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Psychiatric Status Rating Scales; Sodium Oxybate; Temperance | 2006 |
Naltrexone and cognitive behavioral coping skills therapy for the treatment of alcohol drinking and eating disorder features in alcohol-dependent women: a randomized controlled trial.
Topics: Adaptation, Psychological; Adult; Alcohol Drinking; Alcoholism; Attitude; Body Mass Index; Bulimia; Cognitive Behavioral Therapy; Combined Modality Therapy; Depression; Feeding and Eating Disorders; Female; gamma-Glutamyltransferase; Humans; Naltrexone; Narcotic Antagonists; Psychiatric Status Rating Scales; Treatment Outcome | 2007 |
Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study.
Topics: Alcohol Drinking; Alcoholism; Double-Blind Method; Drug Administration Schedule; Fatigue; Female; Finland; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nausea; Patient Compliance; Placebos; Sleep Initiation and Maintenance Disorders; Substance Abuse Treatment Centers; Temperance; Treatment Outcome | 2007 |
Implications of cannabis use and heavy alcohol use on HIV drug risk behaviors in Russian heroin users.
Topics: Adult; Alcohol Drinking; Cannabis; Disease Outbreaks; Female; Heroin Dependence; HIV Infections; Humans; Male; Naltrexone; Risk-Taking; Russia; Sexual Behavior; Treatment Outcome | 2008 |
Family history and antisocial traits moderate naltrexone's effects on heavy drinking in alcoholics.
Topics: Adult; Age of Onset; Alcohol Drinking; Alcoholism; Antisocial Personality Disorder; Cocaine-Related Disorders; Comorbidity; Double-Blind Method; Family; Female; Genetic Predisposition to Disease; Humans; Male; Marijuana Abuse; Naltrexone | 2007 |
Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study.
Topics: Adult; Alcohol Drinking; Alcoholism; Behavior, Addictive; Breath Tests; Double-Blind Method; Emotions; Ethanol; Female; Genetic Variation; Genotype; Humans; Male; Naltrexone; Narcotic Antagonists; Pharmacogenetics; Placebos; Polymorphism, Single Nucleotide; Prospective Studies; Receptors, Opioid, mu; Reward | 2007 |
Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment.
Topics: Adult; Alcohol Drinking; Alcoholism; Counseling; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Female; gamma-Glutamyltransferase; Humans; Injections, Intramuscular; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Prospective Studies; Temperance | 2007 |
Naltrexone is associated with reduced drinking by alcohol dependent patients receiving antidepressants for mood and anxiety symptoms: results from VA Cooperative Study No. 425, "Naltrexone in the treatment of alcoholism".
Topics: Alcohol Drinking; Alcoholism; Antidepressive Agents; Female; Humans; Male; Mood Disorders; Naltrexone; Narcotic Antagonists; Stress Disorders, Post-Traumatic; Treatment Outcome | 2008 |
Hepatic safety of once-monthly injectable extended-release naltrexone administered to actively drinking alcoholics.
Topics: Adult; Alcohol Drinking; Alcoholism; Delayed-Action Preparations; Drug Administration Schedule; Female; Humans; Injections, Intramuscular; Liver; Liver Function Tests; Male; Middle Aged; Naltrexone | 2008 |
Naltrexone in the treatment of alcoholism: predicting response to naltrexone.
Topics: Adult; Aged; Alcohol Drinking; Alcoholism; Ambulatory Care; Combined Modality Therapy; Humans; Male; Middle Aged; Naltrexone; Personality Inventory; Placebos; Probability; Treatment Outcome | 1995 |
Effect of naltrexone on alcohol "high" in alcoholics.
Topics: Alcohol Drinking; Alcoholic Intoxication; Alcoholism; Double-Blind Method; Emotions; Humans; Male; Memory; Naltrexone; Placebos; Temperance | 1995 |
Naltrexone-induced alterations in human ethanol intoxication.
Topics: Administration, Oral; Adult; Affect; Alcohol Drinking; Alcoholic Intoxication; Alcoholism; Ambulatory Care; Animals; Cognition; Double-Blind Method; Ethanol; Female; Humans; Male; Middle Aged; Naltrexone; Placebos; Psychomotor Performance; Recurrence; Sensation | 1994 |
Experience of a "slip" among alcoholics treated with naltrexone or placebo.
Topics: Alcohol Drinking; Alcoholic Intoxication; Alcoholism; Emotions; Humans; Naltrexone; Placebos; Recurrence | 1996 |
Six-month follow-up of naltrexone and psychotherapy for alcohol dependence.
Topics: Adaptation, Psychological; Adult; Alcohol Drinking; Alcoholism; Behavior Therapy; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Male; Naltrexone; Placebos; Psychotherapy; Regression Analysis; Treatment Outcome | 1996 |
The obsessive compulsive drinking scale: A new method of assessing outcome in alcoholism treatment studies.
Topics: Adult; Alcohol Drinking; Alcoholism; Cognitive Behavioral Therapy; Combined Modality Therapy; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Obsessive-Compulsive Disorder; Personality Inventory; Placebos; Psychiatric Status Rating Scales; Psychometrics; Reproducibility of Results; Temperance; Treatment Outcome | 1996 |
Naltrexone increases the latency to drink alcohol in social drinkers.
Topics: Adult; Alcohol Drinking; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Motivation; Naltrexone; Narcotic Antagonists; Reaction Time; Taste | 1996 |
Naltrexone, relapse prevention, and supportive therapy with alcoholics: an analysis of patient treatment matching.
Topics: Adolescent; Adult; Aged; Alcohol Drinking; Alcoholism; Cognitive Behavioral Therapy; Combined Modality Therapy; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Personality Assessment; Recurrence; Treatment Outcome; Verbal Learning | 1996 |
Naltrexone for alcoholic adolescents.
Topics: Adolescent; Alcohol Drinking; Alcoholism; Ambulatory Care; Humans; Naltrexone; Treatment Outcome | 1997 |
Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence.
Topics: Adult; Alcohol Drinking; Alcoholism; Breath Tests; Double-Blind Method; Ethanol; Humans; Male; Naltrexone; Narcotic Antagonists; Risk Factors | 1997 |
Naltrexone and alcohol dependence. Role of subject compliance.
Topics: Adult; Alcohol Drinking; Alcoholism; Clinical Protocols; Combined Modality Therapy; Counseling; Female; Humans; Male; Middle Aged; Naltrexone; Patient Compliance; Placebos; Psychotherapy | 1997 |
Behavioral responses to ethanol in light and moderate social drinkers following naltrexone pretreatment.
Topics: Administration, Oral; Adult; Alcohol Drinking; Alcoholic Intoxication; Arousal; Attention; Breath Tests; Dose-Response Relationship, Drug; Double-Blind Method; Ethanol; Female; Humans; Male; Motivation; Naltrexone; Narcotic Antagonists; Social Environment | 1997 |
Naltrexone treatment of comorbid alcohol and cocaine use disorders.
Topics: Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Cocaine-Related Disorders; Compliance; Double-Blind Method; Female; Humans; Male; Naltrexone | 1998 |
The effects of naltrexone on alcohol and cocaine use in dually addicted patients.
Topics: Adult; Alcohol Drinking; Alcoholism; Ambulatory Care; Cocaine-Related Disorders; Combined Modality Therapy; Comorbidity; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Prevalence; Psychotherapy; Treatment Outcome | 1999 |
Effects of naltrexone on alcohol self-administration in heavy drinkers.
Topics: Adult; Affect; Alcohol Drinking; Beer; Central Nervous System Depressants; Double-Blind Method; Ethanol; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Surveys and Questionnaires | 1999 |
A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence.
Topics: Administration, Oral; Alcohol Drinking; Alcoholism; Breath Tests; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Ethanol; Humans; Naltrexone; Narcotic Antagonists; Placebos; Secondary Prevention; Temperance; Treatment Outcome | 1999 |
Measurement of compliance with naltrexone in the treatment of alcohol dependence: research and clinical implications.
Topics: Alcohol Drinking; Alcoholic Beverages; Alcoholism; Ambulatory Care; Drug Administration Schedule; Drug Monitoring; Drug Packaging; Female; Humans; Male; Microcomputers; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Compliance; Psychiatric Status Rating Scales; Self Administration; Temperance; Treatment Outcome | 1999 |
Non-specific effect of naltrexone on ethanol consumption in social drinkers.
Topics: Adult; Affect; Alcohol Drinking; Breath Tests; Double-Blind Method; Ethanol; Female; Humans; Male; Naltrexone; Narcotic Antagonists | 1999 |
Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial.
Topics: Adult; Alcohol Drinking; Alcoholism; Ambulatory Care; Cognitive Behavioral Therapy; Combined Modality Therapy; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Patient Compliance; Patient Selection; Placebos; Recurrence; Reproducibility of Results; Treatment Outcome | 1999 |
Naltrexone alters subjective and psychomotor responses to alcohol in heavy drinking subjects.
Topics: Adult; Alcohol Drinking; Dose-Response Relationship, Drug; Ethanol; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Psychomotor Performance; Time Factors | 2000 |
Drinking in alcoholics following an alcohol challenge research protocol.
Topics: Adult; Alcohol Drinking; Alcoholism; Female; Humans; Male; Middle Aged; Motivation; Naltrexone; Narcotic Antagonists; Research; Temperance | 2000 |
Naltrexone does not attenuate the acute behavioral effects of ethanol or pentobarbital in humans.
Topics: Adult; Alcohol Drinking; Animals; Behavior, Animal; Central Nervous System Depressants; Double-Blind Method; Drug Interactions; Ethanol; Female; Humans; Hypnotics and Sedatives; Male; Memory; Naltrexone; Narcotic Antagonists; Pentobarbital; Psychomotor Performance; Sleep Stages; Surveys and Questionnaires | 1999 |
Serum 6-beta-naltrexol levels are related to alcohol responses in heavy drinkers.
Topics: Adult; Affect; Alcohol Drinking; Alcoholism; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists | 2000 |
Predictors of compliance with naltrexone among alcoholics.
Topics: Adult; Alcohol Drinking; Alcoholism; Fatigue; Female; Humans; Male; Middle Aged; Naltrexone; Nausea; Patient Compliance; Placebos; Time Factors | 2000 |
Does affect mediate the association between daily events and alcohol use?
Topics: Adolescent; Adult; Affect; Alcohol Drinking; Alcoholism; Arousal; Drug Administration Schedule; Female; Humans; Life Change Events; Male; Middle Aged; Motivation; Naltrexone | 2000 |
Naltrexone's effects on reactivity to alcohol cues among alcoholic men.
Topics: Adult; Alcohol Drinking; Alcoholism; Arousal; Attention; Cues; Humans; Male; Middle Aged; Motivation; Naltrexone; Substance Withdrawal Syndrome; Taste | 2000 |
Combining ondansetron and naltrexone reduces craving among biologically predisposed alcoholics: preliminary clinical evidence.
Topics: Adult; Alcohol Drinking; Alcoholism; Cognitive Behavioral Therapy; Double-Blind Method; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Ondansetron; Serotonin Antagonists | 2001 |
Combining ondansetron and naltrexone treats biological alcoholics: corroboration of self-reported drinking by serum carbohydrate deficient transferrin, a biomarker.
Topics: Adult; Alcohol Drinking; Alcoholism; Biomarkers; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Ondansetron; Placebos; Serotonin Antagonists; Transferrin | 2001 |
Naltrexone dampens ethanol-induced cardiovascular and hypothalamic- pituitary-adrenal axis activation.
Topics: Adult; Alcohol Drinking; Blood Pressure; Central Nervous System Depressants; Drug Interactions; Ethanol; Female; Heart Rate; Hemodynamics; Hormones; Humans; Hypothalamo-Hypophyseal System; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Pituitary-Adrenal System; Skin Temperature | 2001 |
Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes.
Topics: Adaptation, Psychological; Adult; Alcohol Drinking; Alcoholism; Behavior Therapy; Communication; Double-Blind Method; Humans; Liver; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Compliance; Patient Dropouts; Patient Education as Topic; Placebos; Treatment Outcome | 2001 |
Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis.
Topics: Adrenocorticotropic Hormone; Adult; Alcohol Drinking; Alcoholism; Central Nervous System Depressants; Ethanol; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Male; Naltrexone; Narcotic Antagonists; Nausea; Pituitary-Adrenal System; Psychiatric Status Rating Scales; Surveys and Questionnaires | 2002 |
Naltrexone in the treatment of alcohol dependence.
Topics: Adult; Alcohol Drinking; Alcoholism; Ambulatory Care; Combined Modality Therapy; Double-Blind Method; Humans; Male; Naltrexone; Nausea; Patient Dropouts; Placebos; Psychiatric Status Rating Scales; Psychotherapy; Recurrence; Severity of Illness Index; Treatment Outcome | 1992 |
Naltrexone and coping skills therapy for alcohol dependence. A controlled study.
Topics: Adaptation, Psychological; Adult; Alcohol Drinking; Alcoholism; Combined Modality Therapy; Double-Blind Method; Female; Humans; Male; Naltrexone; Person-Centered Psychotherapy; Placebos; Psychiatric Status Rating Scales; Psychotherapy; Recurrence; Severity of Illness Index; Temperance | 1992 |
247 other study(ies) available for naltrexone and Alcohol Drinking
| Article | Year |
|---|---|
Synthesis and biological evaluation of alpha- and beta-6-amido derivatives of 17-cyclopropylmethyl-3, 14beta-dihydroxy-4, 5alpha-epoxymorphinan: potential alcohol-cessation agents.
Topics: Alcohol Drinking; Alcoholism; Amides; Animals; Binding, Competitive; Drug Evaluation, Preclinical; Ethanol; Humans; Hydrogen Bonding; Liver; Mice; Microsomes, Liver; Molecular Structure; Morphinans; Naltrexone; Rats; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu; Stereoisomerism; Structure-Activity Relationship | 2008 |
Commentary on Murphy et al.: What will it take to prescribe extended-release naltrexone to treat alcohol use disorder?
Topics: Alcohol Deterrents; Alcohol Drinking; Alcoholism; Humans; Naltrexone; Narcotic Antagonists | 2022 |
The relationship between drinking and smoking in a clinical trial for smoking cessation and drinking reduction.
Topics: Alcohol Drinking; Naltrexone; Smoking; Smoking Cessation; Treatment Outcome; Varenicline | 2022 |
Examining a brief measure and observed cutoff scores to identify reward and relief drinking profiles: Psychometric properties and pharmacotherapy response.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Female; Humans; Male; Naltrexone; Psychometrics; Reward | 2022 |
Extended-Release Naltrexone and Case Management for Treatment of Alcohol Use Disorder in the Emergency Department.
Topics: Adult; Alcohol Drinking; Alcoholism; Case Management; Humans; Naltrexone; Narcotic Antagonists; Prospective Studies; Quality of Life | 2023 |
Naltrexone and Alcohol Use.
Topics: Alcohol Drinking; Humans; Naltrexone | 2022 |
Naltrexone-induced psychosis in a patient with alcohol use disorder.
Topics: Alcohol Drinking; Alcoholism; Double-Blind Method; Humans; Naltrexone; Psychotic Disorders | 2023 |
Clustering of KOR PET images separates people with AUD into distinct responses to naltrexone.
Topics: Alcohol Drinking; Alcoholism; Humans; Magnetic Resonance Imaging; Naltrexone; Positron-Emission Tomography; Receptors, Opioid, kappa | 2023 |
Education Intervention to Increase Naltrexone Use Among Adult Inpatients With Alcohol Use Disorder.
Topics: Adult; Alcohol Drinking; Alcoholism; Humans; Inpatients; Naltrexone; Narcotic Antagonists | 2023 |
Clinically utilized kappa-opioid receptor agonist nalfurafine combined with low-dose naltrexone prevents alcohol relapse-like drinking in male and female mice.
Topics: Alcohol Drinking; Alcoholism; Analgesics, Opioid; Animals; Drinking; Ethanol; Female; Male; Mice; Mice, Inbred C57BL; Morphinans; Naltrexone; Narcotic Antagonists; Receptors, Opioid, kappa; Receptors, Opioid, mu; Recurrence; Secondary Prevention; Spiro Compounds | 2019 |
Vibration of effects from diverse inclusion/exclusion criteria and analytical choices: 9216 different ways to perform an indirect comparison meta-analysis.
Topics: Alcohol Drinking; Alcoholism; Humans; Meta-Analysis as Topic; Naltrexone; Narcotic Antagonists; Research Design | 2019 |
Nalmefene in alcohol-dependent patients with a high drinking risk: A limited efficacy in reducing alcohol consumption.
Topics: Alcohol Drinking; Alcoholism; Humans; Naltrexone | 2020 |
The selective κ-opioid receptor antagonist JDTic attenuates the alcohol deprivation effect in rats.
Topics: Alcohol Abstinence; Alcohol Deterrents; Alcohol Drinking; Animals; Ethanol; Male; Naltrexone; Narcotic Antagonists; Piperidines; Rats; Rats, Long-Evans; Receptors, Opioid, kappa; Self Administration; Tetrahydroisoquinolines | 2019 |
Effects of the hallucinogenic beverage ayahuasca on voluntary ethanol intake by rats and on cFos expression in brain areas relevant to drug addiction.
Topics: Alcohol Drinking; Animals; Banisteriopsis; Brain; Corpus Striatum; Ethanol; Hallucinogens; Male; Models, Animal; Naltrexone; Narcotic Antagonists; Nucleus Accumbens; Prefrontal Cortex; Proto-Oncogene Proteins c-fos; Rats; Rats, Wistar; Water | 2020 |
Response to 'Nalmefene in alcohol-dependent patients with a high drinking risk: A limited efficacy in reducing alcohol consumption'.
Topics: Alcohol Drinking; Alcoholism; Humans; Naltrexone | 2020 |
OPRM1 Moderates Daily Associations of Naltrexone Adherence With Alcohol Consumption: Preliminary Evidence From a Mobile Health Trial.
Topics: Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Craving; Female; Genotype; Humans; Latent Class Analysis; Male; Medication Adherence; Middle Aged; Multilevel Analysis; Naltrexone; Polymorphism, Genetic; Random Allocation; Receptors, Opioid, mu; Telemedicine | 2020 |
Effects of ethanol, naltrexone, nicotine and varenicline in an ethanol and nicotine co-use model in Sprague-Dawley rats.
Topics: Alcohol Deterrents; Alcohol Drinking; Animals; Ethanol; Female; Male; Naltrexone; Nicotine; Rats; Rats, Sprague-Dawley; Self Administration; Smoking Cessation Agents; Tobacco Use Disorder; Varenicline | 2020 |
Attitudes about medications for alcohol use disorder among individuals with serious mental illness: A health belief model analysis.
Topics: Alcohol Drinking; Alcoholism; Attitude; Female; Health Belief Model; Humans; Infant, Newborn; Male; Naltrexone | 2020 |
Occupancy of the kappa opioid receptor by naltrexone predicts reduction in drinking and craving.
Topics: Alcohol Drinking; Alcoholism; Craving; Humans; Naltrexone; Narcotic Antagonists; Receptors, Opioid, kappa | 2021 |
Pre-training naltrexone increases conditioned fear learning independent of adolescent alcohol consumption history.
Topics: Alcohol Drinking; Animals; Fear; Male; Naltrexone; Narcotic Antagonists; Rats; Rats, Long-Evans; Receptors, Opioid, mu; Underage Drinking | 2021 |
The role of opioidergic system in modulating cost/benefit decision-making in alcohol-preferring AA rats and Wistar rats.
Topics: Alcohol Drinking; Analgesics, Opioid; Animals; Behavior, Animal; Cost-Benefit Analysis; Decision Making; Gambling; Male; Morphine; Naltrexone; Narcotic Antagonists; Rats; Rats, Wistar; Reward; Sucrose | 2021 |
Baclofen and naltrexone, but not N-acetylcysteine, affect voluntary alcohol drinking in rats regardless of individual levels of alcohol intake.
Topics: Acetylcysteine; Alcohol Drinking; Animals; Baclofen; Ethanol; GABA-B Receptor Agonists; Male; Naltrexone; Narcotic Antagonists; Rats | 2021 |
[Four cases of alcoholic liver cirrhosis in alcohol-dependent patients treated with nalmefene].
Topics: Alcohol Drinking; Alcoholism; Europe; Humans; Japan; Liver Cirrhosis, Alcoholic; Naltrexone | 2021 |
Effects of 5-HT2A receptor agonist 2,5-dimethoxy-4-iodoamphetamine on alcohol consumption in Long-Evans rats.
Topics: Alcohol Deterrents; Alcohol Drinking; Alcoholism; Amphetamines; Animals; Central Nervous System Depressants; Drug Interactions; Ethanol; Hallucinogens; Male; Naltrexone; Rats; Rats, Long-Evans; Serotonin 5-HT2 Receptor Agonists | 2021 |
The administration of sertraline plus naltrexone reduces ethanol consumption and motivation in a long-lasting animal model of post-traumatic stress disorder.
Topics: Alcohol Deterrents; Alcohol Drinking; Animals; Antidepressive Agents; Disease Models, Animal; Drug Therapy, Combination; Male; Mice; Mice, Inbred C57BL; Motivation; Naltrexone; Self Administration; Serotonin Plasma Membrane Transport Proteins; Sertraline; Stress Disorders, Post-Traumatic; Stress, Psychological; Time Factors | 2021 |
Combined varenicline and naltrexone attenuates alcohol cue-elicited activation in heavy drinking smokers.
Topics: Alcohol Drinking; Alcoholism; Cues; Double-Blind Method; Humans; Naltrexone; Smokers; Varenicline | 2021 |
Implementation of Oral and Extended-Release Naltrexone for the Treatment of Emergency Department Patients With Moderate to Severe Alcohol Use Disorder: Feasibility and Initial Outcomes.
Topics: Adolescent; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; California; Delayed-Action Preparations; Emergency Service, Hospital; Emergency Treatment; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Young Adult | 2021 |
Evaluation of effect of minocycline on rewarding potential and alcohol relapse in place preference model in mice.
Topics: Alcohol Drinking; Alcoholism; Animals; Conditioning, Classical; Conditioning, Operant; Disease Models, Animal; Ethanol; Extinction, Psychological; Male; Mice; Minocycline; Naltrexone; Reward; Secondary Prevention | 2017 |
Nalmefene Prevents Alcohol-Induced Neuroinflammation and Alcohol Drinking Preference in Adolescent Female Mice: Role of TLR4.
Topics: Alcohol Drinking; Alcohol-Related Disorders; Animals; Astrocytes; Cell Death; Chemokines; Drug Evaluation, Preclinical; Ethanol; Female; Membrane Microdomains; Mice, Inbred C57BL; Mice, Knockout; Myelin Sheath; Naloxone; Naltrexone; Narcotic Antagonists; Primary Cell Culture; Toll-Like Receptor 4 | 2017 |
Restraint stress enhances alcohol intake in adolescent female rats but reduces alcohol intake in adolescent male and adult female rats.
Topics: Aging; Alcohol Drinking; Animals; Central Nervous System Depressants; Choice Behavior; Disease Models, Animal; Ethanol; Exploratory Behavior; Female; Male; Motor Activity; Naltrexone; Narcotic Antagonists; Rats, Wistar; Receptors, Opioid, kappa; Restraint, Physical; Risk-Taking; Sex Characteristics; Stress, Psychological | 2017 |
Baclofen and naltrexone effects on alcohol self-administration: Comparison of treatment initiated during abstinence or ongoing alcohol access in baboons.
Topics: Alcohol Abstinence; Alcohol Drinking; Alcoholism; Animals; Baclofen; Disease Models, Animal; GABA-B Receptor Agonists; Naltrexone; Papio; Reinforcement, Psychology; Self Administration | 2017 |
Increased ethanol drinking in "humanized" mice expressing the mu opioid receptor A118G polymorphism are mediated through sex-specific mechanisms.
Topics: Alcohol Drinking; Alleles; Analgesics, Non-Narcotic; Analysis of Variance; Animals; Choice Behavior; Conditioning, Operant; Dose-Response Relationship, Drug; Ethanol; Female; Genotype; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mutagenesis, Site-Directed; Naltrexone; Narcotic Antagonists; Polymorphism, Single Nucleotide; Quinine; Receptors, Opioid, mu; Reflex; Reward; Self Administration; Self Stimulation; Sex Characteristics | 2018 |
Cost-Effectiveness of Nalmefene Added to Psychosocial Support for the Reduction of Alcohol Consumption in Alcohol-Dependent Patients With High/Very High Drinking Risk Levels: A Microsimulation Model.
Topics: Alcohol Drinking; Alcoholism; Cost-Benefit Analysis; Female; Humans; Male; Middle Aged; Naltrexone; Quality-Adjusted Life Years; Risk | 2017 |
V1b Receptor Antagonist SSR149415 and Naltrexone Synergistically Decrease Excessive Alcohol Drinking in Male and Female Mice.
Topics: Alcohol Drinking; Animals; Antidiuretic Hormone Receptor Antagonists; Drug Synergism; Drug Therapy, Combination; Female; Indoles; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Naltrexone; Narcotic Antagonists; Pyrrolidines; Receptors, Vasopressin | 2018 |
Effectiveness of extended release naltrexone to reduce alcohol cravings and use behaviors during treatment and at follow-up.
Topics: Adult; Alcohol Deterrents; Alcohol Drinking; Craving; Delayed-Action Preparations; Female; Follow-Up Studies; Humans; Male; Naltrexone; Substance-Related Disorders | 2018 |
Co-Administration of Low-Dose Naltrexone and Bupropion Reduces Alcohol Drinking in Alcohol-Preferring (P) Rats.
Topics: Alcohol Deterrents; Alcohol Drinking; Animals; Behavior, Animal; Bupropion; Central Nervous System Depressants; Dopamine Uptake Inhibitors; Ethanol; Male; Naltrexone; Rats; Self Administration | 2018 |
Commentary on Palpacuer et al. (2018): Do small effects on total alcohol consumption translate into clinical practice?
Topics: Acamprosate; Alcohol Drinking; Alcoholism; Baclofen; Humans; Naltrexone; Narcotic Antagonists; Network Meta-Analysis; Topiramate | 2018 |
Effects of mesyl salvinorin B alone and in combination with naltrexone on alcohol deprivation effect in male and female mice.
Topics: Alcohol Drinking; Animals; Diterpenes; Diterpenes, Clerodane; Ethanol; Female; Male; Mesylates; Mice, Inbred C57BL; Naltrexone; Narcotic Antagonists; Receptors, Opioid, kappa; Recurrence | 2018 |
Exploring Sex Differences in the Attenuation of Ethanol Drinking by Naltrexone in Dependent Rats During Early and Protracted Abstinence.
Topics: Administration, Inhalation; Alcohol Abstinence; Alcohol Drinking; Alcoholism; Animals; Ethanol; Female; Male; Motivation; Naltrexone; Narcotic Antagonists; Rats; Rats, Wistar; Self Administration; Sex Characteristics; Substance Withdrawal Syndrome | 2018 |
An improved model of ethanol and nicotine co-use in female P rats: Effects of naltrexone, varenicline, and the selective nicotinic α6β2* antagonist r-bPiDI.
Topics: Alcohol Deterrents; Alcohol Drinking; Animals; Disease Models, Animal; Ethanol; Female; Naltrexone; Nicotine; Nicotinic Antagonists; Picolines; Pyridinium Compounds; Rats; Self Administration; Smoking Cessation Agents; Tobacco Use Disorder; Treatment Outcome; Varenicline | 2018 |
Distress Tolerance and Craving for Cigarettes Among Heavy Drinking Smokers.
Topics: Adult; Alcohol Drinking; Alcoholism; Cigarette Smoking; Craving; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Random Allocation; Smokers; Smoking Cessation; Stress, Psychological; Varenicline; Young Adult | 2018 |
Therapeutic challenges for concurrent ethanol and nicotine consumption: naltrexone and varenicline fail to alter simultaneous ethanol and nicotine intake by female alcohol-preferring (P) rats.
Topics: Alcohol Deterrents; Alcohol Drinking; Animals; Ethanol; Female; Injections, Subcutaneous; Naltrexone; Nicotine; Random Allocation; Rats; Self Administration; Smoking Cessation Agents; Tobacco Use Disorder; Varenicline | 2019 |
Target Population, Dose, and Timing Considerations for Understanding Naltrexone's Subjective Effect: Response to Amiaz.
Topics: Alcohol Drinking; Alcoholism; Antidepressive Agents; Humans; Ketamine; Naltrexone; Narcotic Antagonists; Population; Receptors, Opioid | 2019 |
Therapeutic Drug Monitoring and the Clinical Significance of Naltrexone Blood Levels at the Time of a First Drink: Relevance to the Sinclair Method.
Topics: Alcohol Drinking; Alcoholism; Drug Monitoring; Humans; Naltrexone; Narcotic Antagonists; Time Factors | 2019 |
Combination of Clinically Utilized Kappa-Opioid Receptor Agonist Nalfurafine With Low-Dose Naltrexone Reduces Excessive Alcohol Drinking in Male and Female Mice.
Topics: Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Animals; Drug Evaluation, Preclinical; Drug Tolerance; Female; Male; Mice, Inbred C57BL; Morphinans; Naltrexone; Receptors, Opioid, kappa; Saccharin; Spiro Compounds; Sucrose | 2019 |
Effects of stimulation of mu opioid and nociceptin/orphanin FQ peptide (NOP) receptors on alcohol drinking in rhesus monkeys.
Topics: Alcohol Drinking; Animals; Azabicyclo Compounds; Buprenorphine; Dose-Response Relationship, Drug; Eating; Macaca mulatta; Male; Naltrexone; Nociceptin Receptor; Receptors, Opioid; Receptors, Opioid, mu | 2019 |
Effects of naltrexone on post-abstinence alcohol drinking in C57BL/6NCRL and DBA/2J mice.
Topics: Alcohol Abstinence; Alcohol Drinking; Analysis of Variance; Animals; Central Nervous System Depressants; Disease Models, Animal; Dose-Response Relationship, Drug; Drinking Behavior; Ethanol; Food Preferences; Male; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Naltrexone; Narcotic Antagonists; Species Specificity; Time Factors | 2013 |
Activation of PPARγ by pioglitazone potentiates the effects of naltrexone on alcohol drinking and relapse in msP rats.
Topics: Alcohol Drinking; Animals; Cues; Drug Evaluation, Preclinical; Drug Therapy, Combination; Hypoglycemic Agents; Male; Naltrexone; Narcotic Antagonists; Pioglitazone; PPAR gamma; Rats; Thiazolidinediones; Yohimbine | 2013 |
Effects of naltrexone plus topiramate on ethanol self-administration and tyrosine hydroxylase gene expression changes.
Topics: Administration, Oral; Alcohol Drinking; Analysis of Variance; Animals; Central Nervous System Agents; Central Nervous System Depressants; Conditioning, Operant; Drug Combinations; Ethanol; Fructose; Gene Expression; Mice, Inbred C57BL; Motivation; Naltrexone; Self Administration; Topiramate; Tyrosine 3-Monooxygenase; Ventral Tegmental Area | 2014 |
Effects of the kappa opioid receptor antagonist, nor-binaltorphimine, on ethanol intake: impact of age and sex.
Topics: Age Factors; Alcohol Drinking; Animals; Conditioning, Operant; Drinking Behavior; Ethanol; Female; Male; Naltrexone; Narcotic Antagonists; Rats; Self Administration; Sex Factors | 2014 |
Combining naltrexone and prazosin in a single oral medication decreases alcohol drinking more effectively than does either drug alone.
Topics: Administration, Oral; Adrenergic alpha-1 Receptor Antagonists; Alcohol Drinking; Alcoholism; Animals; Drug Combinations; Drug Synergism; Male; Naltrexone; Narcotic Antagonists; Prazosin; Rats; Rats, Wistar; Treatment Outcome | 2013 |
Reduction of excessive alcohol drinking by a novel GABAB receptor positive allosteric modulator ADX71441 in mice.
Topics: Acetamides; Alcohol Deterrents; Alcohol Drinking; Allosteric Regulation; Animals; Bacterial Proteins; Binge Drinking; Disease Models, Animal; Dose-Response Relationship, Drug; Drinking; GABA-B Receptor Agonists; Male; Mice; Naltrexone; Transcription Factors; Triazines | 2014 |
Commentary on Subbaraman et al. (2013) [corrected]: cravings as a mediator and moderator of drinking outcomes in the COMBINE Study.
Topics: Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior Therapy; Humans; Naltrexone; Narcotic Antagonists | 2013 |
KASL clinical practice guidelines: management of alcoholic liver disease.
Topics: Alcohol Abstinence; Alcohol Drinking; Alcohol-Related Disorders; Baclofen; Disulfiram; Fatty Liver, Alcoholic; Hepatitis, Alcoholic; Humans; Liver Cirrhosis; Liver Diseases, Alcoholic; Naltrexone; Prevalence; Prognosis; Risk Factors; Severity of Illness Index; Surveys and Questionnaires | 2013 |
The efficacy of a low dose combination of topiramate and naltrexone on ethanol reinforcement and consumption in rat models.
Topics: Alcohol Drinking; Animals; Dose-Response Relationship, Drug; Drug Combinations; Ethanol; Fructose; Models, Animal; Naltrexone; Rats; Rats, Wistar; Topiramate | 2014 |
Improved effect of the combination naltrexone/D-penicillamine in the prevention of alcohol relapse-like drinking in rats.
Topics: Alcohol Deterrents; Alcohol Drinking; Animals; Drug Therapy, Combination; Infusions, Subcutaneous; Injections, Subcutaneous; Male; Naltrexone; Narcotic Antagonists; Penicillamine; Rats; Secondary Prevention | 2014 |
Nalmefene in alcohol misuse: junk evaluation by the European Medicines Agency.
Topics: Alcohol Drinking; Alcoholism; Humans; Naltrexone | 2014 |
Bad medicine: using surrogate markers.
Topics: Alcohol Drinking; Alcoholism; Humans; Naltrexone | 2014 |
Wim van den Brink and colleagues reply to Des Spence and Alain Braillon.
Topics: Alcohol Drinking; Alcoholism; Humans; Naltrexone | 2014 |
Light alcohol intake during adolescence induces alcohol addiction in a neurodevelopmental model of schizophrenia.
Topics: Alcohol Drinking; Alcoholism; Animals; Animals, Newborn; Central Nervous System Depressants; Conditioning, Operant; Disease Models, Animal; Drug-Seeking Behavior; Ethanol; Hippocampus; Male; Naltrexone; Narcotic Antagonists; Rats, Sprague-Dawley; Schizophrenia | 2015 |
Brief prenatal ethanol exposure alters behavioral sensitivity to the kappa opioid receptor agonist (U62,066E) and antagonist (Nor-BNI) and reduces kappa opioid receptor expression.
Topics: Alcohol Drinking; Animals; Brain Chemistry; Conditioning, Psychological; Ethanol; Female; Gene Expression; Male; Naltrexone; Pregnancy; Prenatal Exposure Delayed Effects; Pyrrolidines; Rats, Sprague-Dawley; Receptors, Opioid, kappa | 2014 |
▼Nalmefene for alcohol dependence.
Topics: Alcohol Drinking; Alcoholism; Drug Approval; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Prevalence; Sex Factors; United Kingdom | 2014 |
Difference of the naltrexone's effects in social drinkers by spicy food preference.
Topics: Adult; Alcohol Drinking; Alcoholism; Capsaicin; Food Preferences; Humans; Male; Naltrexone; Narcotic Antagonists; Sensory System Agents; Surveys and Questionnaires; Young Adult | 2014 |
Chronic treatment with novel brain-penetrating selective NOP receptor agonist MT-7716 reduces alcohol drinking and seeking in the rat.
Topics: Acenaphthenes; Alcohol Deterrents; Alcohol Drinking; Animals; Benzimidazoles; Choice Behavior; Dose-Response Relationship, Drug; Drug-Seeking Behavior; HEK293 Cells; Humans; Male; Naltrexone; Narcotic Antagonists; Nociceptin; Nociceptin Receptor; Opioid Peptides; Rats; Rats, Wistar; Receptors, Opioid; Stress, Psychological; Substance Withdrawal Syndrome | 2014 |
Changes in hospital and out-patient events and costs following implant naltrexone treatment for problematic alcohol use.
Topics: Adolescent; Adult; Aged; Alcohol Drinking; Australia; Delayed-Action Preparations; Drug Implants; Female; Health Care Costs; Hospitalization; Humans; Male; Mental Health Services; Middle Aged; Naltrexone; Outpatients; Patient Acceptance of Health Care; Young Adult | 2014 |
Salsolinol, free of isosalsolinol, exerts ethanol-like motivational/sensitization effects leading to increases in ethanol intake.
Topics: Alcohol Drinking; Animals; Conditioning, Psychological; Female; Isoquinolines; Motivation; Motor Activity; Naltrexone; Rats; Rats, Wistar; Ventral Tegmental Area | 2014 |
Nalmefene. Alcohol dependence: no advance.
Topics: Alcohol Drinking; Alcoholism; Humans; Naltrexone; Narcotic Antagonists; Patient Safety; Patient Selection; Risk Assessment; Risk Factors; Treatment Outcome | 2014 |
A predictive microsimulation model to estimate the clinical relevance of reducing alcohol consumption in alcohol dependence.
Topics: Adult; Alcohol Drinking; Alcohol-Related Disorders; Alcoholism; Computer Simulation; England; Female; Harm Reduction; Humans; Logistic Models; Male; Middle Aged; Models, Theoretical; Naltrexone; Narcotic Antagonists; Wounds and Injuries | 2014 |
Dissociation of μ-opioid receptor and CRF-R1 antagonist effects on escalated ethanol consumption and mPFC serotonin in C57BL/6J mice.
Topics: Alcohol Drinking; Aminopyridines; Animals; Behavior, Animal; Central Nervous System Depressants; Dorsal Raphe Nucleus; Ethanol; Immunohistochemistry; Infusions, Intraventricular; Male; Mice; Mice, Inbred C57BL; Microdialysis; Naltrexone; Narcotic Antagonists; Prefrontal Cortex; Pyrimidines; Pyrroles; Receptors, Corticotropin-Releasing Hormone; Receptors, Opioid, mu; Self Administration; Serotonin; Tryptophan Hydroxylase | 2016 |
Predictors of abstinence from heavy drinking during treatment in COMBINE and external validation in PREDICT.
Topics: Acamprosate; Age Factors; Alcohol Abstinence; Alcohol Deterrents; Alcohol Drinking; Behavior Therapy; Combined Modality Therapy; Controlled Clinical Trials as Topic; Decision Trees; gamma-Glutamyltransferase; Germany; Goals; Humans; Logistic Models; Middle Aged; Naltrexone; Predictive Value of Tests; Randomized Controlled Trials as Topic; Reproducibility of Results; Taurine; Time Factors; Treatment Outcome; United States | 2014 |
Evaluation of guanfacine as a potential medication for alcohol use disorder in long-term drinking rats: behavioral and electrophysiological findings.
Topics: Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Animals; Central Nervous System Depressants; Choice Behavior; Conditioning, Operant; Disease Models, Animal; Drug Evaluation, Preclinical; Drug-Seeking Behavior; Ethanol; Glutamic Acid; Guanfacine; Male; Naltrexone; Prefrontal Cortex; Pyramidal Cells; Rats, Wistar; Tissue Culture Techniques; Treatment Outcome | 2015 |
A pharmacogenetic determinant of mu-opioid receptor antagonist effects on alcohol reward and consumption: evidence from humanized mice.
Topics: Alcohol Drinking; Animals; Conditioning, Operant; Electric Stimulation; Ethanol; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Naltrexone; Receptors, Opioid, mu; Reward; Self Administration | 2015 |
Comparison of dehydroepiandrosterone (DHEA) and pregnanolone with existing pharmacotherapies for alcohol abuse on ethanol- and food-maintained responding in male rats.
Topics: Acamprosate; Alcohol Drinking; Alcoholism; Animals; Dehydroepiandrosterone; Dose-Response Relationship, Drug; Eating; Ethanol; Male; Naltrexone; Pregnanolone; Rats; Rats, Long-Evans; Self Administration; Taurine | 2015 |
Naltrexone reduces heavy drinking in problem drinkers across the spectrum of dependence.
Topics: Alcohol Drinking; Alcoholism; Female; Humans; Male; Naltrexone | 2015 |
Complexities of the mu opioid receptor.
Topics: Alcohol Drinking; Animals; Humans; Male; Naltrexone; Receptors, Opioid, mu; Reward | 2015 |
The Novel μ-Opioid Receptor Antagonist GSK1521498 Decreases Both Alcohol Seeking and Drinking: Evidence from a New Preclinical Model of Alcohol Seeking.
Topics: Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Animals; Blood Alcohol Content; Choice Behavior; Conditioning, Operant; Cues; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug-Seeking Behavior; Indans; Male; Naltrexone; Narcotic Antagonists; Rats; Receptors, Opioid, mu; Reinforcement, Psychology; Species Specificity; Triazoles | 2015 |
The Effects of as-Needed Nalmefene on Patient-Reported Outcomes and Quality of Life in Relation to a Reduction in Alcohol Consumption in Alcohol-Dependent Patients.
Topics: Adult; Alcohol Drinking; Alcoholism; Demography; Female; Humans; Male; Middle Aged; Naltrexone; Patient Outcome Assessment; Quality of Life; Surveys and Questionnaires; Treatment Outcome | 2015 |
Influence of the A118G Polymorphism of the OPRM1 Gene and Exon 3 VNTR Polymorphism of the DRD4 Gene on Cigarette Craving After Alcohol Administration.
Topics: Adult; Alcohol Drinking; Alleles; Craving; Exons; Female; Genotype; Humans; Male; Minisatellite Repeats; Naltrexone; Narcotic Antagonists; Polymorphism, Genetic; Receptors, Opioid, mu; Smoking; Smoking Cessation | 2016 |
The novel mu-opioid antagonist, GSK1521498, reduces ethanol consumption in C57BL/6J mice.
Topics: Alcohol Drinking; Alcoholism; Animals; Autoradiography; Behavior, Animal; Central Nervous System Depressants; Cross-Over Studies; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Ethanol; Indans; Male; Mice; Mice, Inbred C57BL; Naltrexone; Narcotic Antagonists; Radiopharmaceuticals; Receptors, Opioid, mu; Self Administration; Triazoles; Tritium | 2015 |
Prazosin + Naltrexone Decreases Alcohol Drinking More Effectively Than Does Either Drug Alone in P Rats with a Protracted History of Extensive Voluntary Alcohol Drinking, Dependence, and Multiple Withdrawals.
Topics: Adrenergic alpha-1 Receptor Antagonists; Alcohol Drinking; Alcoholism; Animals; Drug Therapy, Combination; Male; Naltrexone; Narcotic Antagonists; Prazosin; Rats; Substance Withdrawal Syndrome; Treatment Outcome | 2015 |
Oral operant ethanol self-administration in the absence of explicit cues, food restriction, water restriction and ethanol fading in C57BL/6J mice.
Topics: Administration, Oral; Alcohol Drinking; Animals; Conditioning, Operant; Cues; Ethanol; Food Deprivation; Male; Mice; Mice, Inbred C57BL; Naltrexone; Reinforcement, Psychology; Saccharin; Self Administration; Water | 2015 |
[Reduction of consumption as the first goal of therapy].
Topics: Alcohol Drinking; Alcoholism; Humans; Naltrexone; Narcotic Antagonists | 2015 |
[Alcohol use disorders: current approaches to diagnosis and treatment].
Topics: Alcohol Drinking; Alcoholism; Diagnostic and Statistical Manual of Mental Disorders; Ethanol; Female; Humans; International Classification of Diseases; Male; Naltrexone; Narcotic Antagonists; Remission Induction | 2015 |
Nalmefene Mistakenly Prescribed to Reduce Alcohol Consumption in Patients Under Buprenorphine Substitution Therapy Resulting in Acute Opioid Withdrawal: Management in an Emergency Setting.
Topics: Adult; Alcohol Drinking; Analgesics, Opioid; Buprenorphine; Drug Interactions; Female; Humans; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Substance Withdrawal Syndrome | 2016 |
Association between a brief alcohol craving measure and drinking in the following week.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Cognitive Behavioral Therapy; Craving; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Odds Ratio; Randomized Controlled Trials as Topic; Taurine; United States | 2016 |
Modulation of nucleus accumbens connectivity by alcohol drinking and naltrexone in alcohol-preferring rats: A manganese-enhanced magnetic resonance imaging study.
Topics: Alcohol Abstinence; Alcohol Drinking; Analysis of Variance; Animals; Chlorides; Conditioning, Operant; Disease Models, Animal; Ethanol; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Manganese Compounds; Naltrexone; Narcotic Antagonists; Nucleus Accumbens; Rats; Time Factors | 2016 |
Sodium oxybate plus nalmefene for the treatment of alcohol use disorder: A case series.
Topics: Adult; Alcohol Abstinence; Alcohol Drinking; Alcohol-Related Disorders; Alcoholism; Alcohols; Craving; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Sodium Oxybate; Treatment Outcome | 2016 |
The Cost Effectiveness of Nalmefene for Reduction of Alcohol Consumption in Alcohol-Dependent Patients with High or Very High Drinking-Risk Levels from a UK Societal Perspective.
Topics: Adolescent; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Combined Modality Therapy; Cost of Illness; Cost-Benefit Analysis; Crime; Efficiency; Female; Health Care Costs; Humans; Male; Markov Chains; Middle Aged; Models, Economic; Naltrexone; Patient Acceptance of Health Care; Psychotherapy; Risk; United Kingdom; Young Adult | 2016 |
Nalmefene is effective at reducing alcohol seeking, treating alcohol-cocaine interactions and reducing alcohol-induced histone deacetylases gene expression in blood.
Topics: Alcohol Drinking; Animals; Cocaine; Dose-Response Relationship, Drug; Drug Interactions; Ethanol; Gene Expression Regulation, Enzymologic; Histone Deacetylases; Male; Naltrexone; Rats; Rats, Wistar; Structure-Activity Relationship | 2016 |
Multi-modal MRI classifiers identify excessive alcohol consumption and treatment effects in the brain.
Topics: Alcohol Drinking; Alcoholism; Animals; Brain; Central Nervous System Depressants; Disease Models, Animal; Ethanol; Longitudinal Studies; Magnetic Resonance Imaging; Naltrexone; Narcotic Antagonists; Rats | 2017 |
A Trial-Based Predictive Microsimulation Assessing the Public Health Benefits of Nalmefene and Psychosocial Support for the Reduction of Alcohol Consumption in Alcohol Dependence.
Topics: Alcohol Drinking; Alcoholism; Clinical Trials as Topic; Computer Simulation; Europe; Harm Reduction; Humans; Multicenter Studies as Topic; Naltrexone; Narcotic Antagonists; Outcome and Process Assessment, Health Care; Public Health; Social Support | 2016 |
Combining Varenicline (Chantix) with Naltrexone Decreases Alcohol Drinking More Effectively Than Does Either Drug Alone in a Rodent Model of Alcoholism.
Topics: Alcohol Drinking; Alcoholism; Animals; Dose-Response Relationship, Drug; Drug Therapy, Combination; Male; Models, Animal; Naltrexone; Narcotic Antagonists; Nicotinic Agonists; Rats; Rodentia; Treatment Outcome; Varenicline | 2016 |
A Comparison of Markov and Discrete-Time Microsimulation Approaches: Simulating the Avoidance of Alcohol-Attributable Harmful Events from Reduction of Alcohol Consumption Through Treatment of Alcohol Dependence.
Topics: Adult; Alcohol Drinking; Alcohol-Related Disorders; Alcoholism; Female; Humans; Naltrexone | 2016 |
Comment on: "Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence".
Topics: Alcohol Drinking; Alcoholism; Humans; Naltrexone | 2016 |
Evaluation in alcohol use disorders - insights from the nalmefene experience.
Topics: Adult; Alcohol Abstinence; Alcohol Drinking; Alcoholism; Female; Harm Reduction; Humans; Male; Naltrexone; Narcotic Antagonists | 2016 |
Hypothalamic-specific proopiomelanocortin deficiency reduces alcohol drinking in male and female mice.
Topics: Adrenal Insufficiency; Alcohol Drinking; Animals; Ethanol; Female; Genotype; Hypothalamus; Male; Mice; Mice, Knockout; Naltrexone; Obesity; Pro-Opiomelanocortin | 2017 |
A Combination of Naltrexone + Varenicline Retards the Expression of a Genetic Predisposition Toward High Alcohol Drinking.
Topics: Alcohol Drinking; Animals; Drug Therapy, Combination; Genetic Predisposition to Disease; Male; Naltrexone; Narcotic Antagonists; Nicotinic Agonists; Rats; Varenicline | 2017 |
Synergistic blockade of alcohol escalation drinking in mice by a combination of novel kappa opioid receptor agonist Mesyl Salvinorin B and naltrexone.
Topics: Alcohol Drinking; Alcoholism; Animals; Central Nervous System Agents; Diterpenes; Diterpenes, Clerodane; Drinking; Ethanol; Female; Male; Mesylates; Mice; Naltrexone; Narcotic Antagonists; Receptors, Opioid, kappa; Receptors, Opioid, mu | 2017 |
Effects of CRF1-receptor and opioid-receptor antagonists on dependence-induced increases in alcohol drinking by alcohol-preferring (P) rats.
Topics: Alcohol Drinking; Alcoholism; Animals; Central Nervous System Depressants; Disease Models, Animal; Dose-Response Relationship, Drug; Drinking Behavior; Ethanol; Food Preferences; Male; Naltrexone; Narcotic Antagonists; Pyrimidines; Rats; Rats, Wistar; Receptors, Corticotropin-Releasing Hormone; Receptors, Opioid | 2008 |
Electroacupuncture reduces voluntary alcohol intake in alcohol-preferring rats via an opiate-sensitive mechanism.
Topics: Alcohol Drinking; Animals; Electroacupuncture; Naltrexone; Narcotic Antagonists; Rats; Receptors, Opioid | 2008 |
Intermittent access to 20% ethanol induces high ethanol consumption in Long-Evans and Wistar rats.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Animals; Ethanol; Male; Models, Animal; Naltrexone; Narcotic Antagonists; Rats; Rats, Long-Evans; Rats, Wistar; Taurine; Time Factors | 2008 |
Naltrexone treatment produces dose-related effects on food and water intake but daily alcohol consumption is not affected.
Topics: Alcohol Drinking; Animals; Dose-Response Relationship, Drug; Drinking; Eating; Male; Naltrexone; Narcotic Antagonists; Rats; Rats, Wistar | 2008 |
Negative symptoms are associated with less alcohol use, craving, and "high" in alcohol dependent patients with schizophrenia.
Topics: Adult; Alcohol Drinking; Alcoholism; Behavior, Addictive; Cocaine-Related Disorders; Cognition Disorders; Comorbidity; Diagnostic and Statistical Manual of Mental Disorders; Euphoria; Female; Humans; Male; Marijuana Abuse; Naltrexone; Narcotic Antagonists; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index | 2008 |
Effect of naltrexone during extinction of alcohol-reinforced responding and during repeated cue-conditioned reinstatement sessions in a cue exposure style treatment.
Topics: Alcohol Drinking; Animals; Conditioning, Psychological; Cues; Ethanol; Extinction, Psychological; Male; Naltrexone; Rats; Rats, Long-Evans | 2008 |
The effects of extended-release naltrexone on holiday drinking in alcohol-dependent patients.
Topics: Adult; Aged; Alcohol Drinking; Alcoholism; Delayed-Action Preparations; Female; Holidays; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Social Support; Temperance; Young Adult | 2009 |
Disposition of naltrexone after intravenous bolus administration in Wistar rats, low-alcohol-drinking rats and high-alcohol-drinking rats.
Topics: Alcohol Drinking; Animals; Behavior, Animal; Chromatography, High Pressure Liquid; Injections, Intravenous; Male; Naltrexone; Narcotic Antagonists; Rats; Rats, Wistar; Time Factors | 2008 |
Persistence with oral naltrexone for alcohol treatment: implications for health-care utilization.
Topics: Adult; Aged; Alcohol Drinking; Alcoholism; Drug Prescriptions; England; Female; Health Services; Humans; Male; Medication Adherence; Middle Aged; Naltrexone; Narcotic Antagonists; Retrospective Studies; Young Adult | 2008 |
Holidays, triggers, and willpower--is there a role for medications? A commentary on "The effects of extended-release naltrexone on holiday drinking in alcohol-dependent patients".
Topics: Alcohol Drinking; Alcoholism; Delayed-Action Preparations; Holidays; Humans; Naltrexone; Narcotic Antagonists | 2009 |
Acamprosate and naltrexone treatment effects on ethanol and sucrose seeking and intake in ethanol-dependent and nondependent rats.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Body Weight; Conditioning, Operant; Data Interpretation, Statistical; Male; Naltrexone; Rats; Rats, Long-Evans; Sucrose; Taste; Taurine | 2009 |
Potency of naltrexone to reduce ethanol self-administration in rats is greater for subcutaneous versus intraperitoneal injection.
Topics: Alcohol Drinking; Animals; Conditioning, Operant; Ethanol; Injections, Intraperitoneal; Injections, Subcutaneous; Male; Naltrexone; Narcotic Antagonists; Rats; Rats, Long-Evans; Receptors, Opioid; Self Administration | 2009 |
Appetitive motivational experience during adolescence results in enhanced alcohol consumption during adulthood.
Topics: Aging; Alcohol Drinking; Analysis of Variance; Animals; Appetitive Behavior; Dietary Sucrose; Dose-Response Relationship, Drug; Drinking Behavior; Ethanol; Male; Motivation; Naltrexone; Narcotic Antagonists; Rats; Rats, Wistar; Self Administration; Time Factors | 2009 |
Opioid antagonists block the acquisition of ethanol-mediated conditioned tactile preference in infant rats.
Topics: Alcohol Drinking; Alcoholic Intoxication; Animals; Animals, Newborn; Conditioning, Classical; Ethanol; Naloxone; Naltrexone; Narcotic Antagonists; Rats; Touch | 2009 |
Alcohol dependence: after the withdrawal phase. Long-term abstinence: better health and psychosocial status. Psychosocial support for a chronic disorder. Some drugs are useful adjuncts to medical support.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Alcoholics; Alcoholism; Anticonvulsants; Baclofen; Clinical Trials as Topic; Combined Modality Therapy; Disulfiram; France; Fructose; Health Status; Humans; Naltrexone; Psychotherapy; Randomized Controlled Trials as Topic; Secondary Prevention; Self-Help Groups; Social Support; Taurine; Temperance; Topiramate; Treatment Outcome | 2009 |
Chronic naltrexone treatment and ethanol responsivity in outbred rats.
Topics: Alcohol Drinking; Animals; Behavior, Animal; Central Nervous System Depressants; Ethanol; Fistula; Infusion Pumps, Implantable; Male; Mouth; Naltrexone; Narcotic Antagonists; Rats; Rats, Long-Evans; Taste; Videotape Recording | 2010 |
Naltrexone and combined behavioral intervention effects on trajectories of drinking in the COMBINE study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Behavior Therapy; Combined Modality Therapy; Drug Therapy, Combination; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Odds Ratio; Randomized Controlled Trials as Topic; Taurine; Treatment Outcome; United States | 2010 |
A pharmacogenetic model of naltrexone-induced attenuation of alcohol consumption in rhesus monkeys.
Topics: Alcohol Drinking; Animals; Central Nervous System Depressants; Conditioning, Operant; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Ethanol; Fluorescence Resonance Energy Transfer; Genotype; Macaca mulatta; Male; Naltrexone; Narcotic Antagonists; Pharmacogenetics; Polymorphism, Single Nucleotide; Receptors, Opioid, mu; Reinforcement Schedule | 2010 |
Artificial microRNA-based neurokinin-1 receptor gene silencing reduces alcohol consumption in mice.
Topics: Alcohol Drinking; Animals; Brain; Gene Knockdown Techniques; Lentivirus; Male; Mice; Mice, Inbred C57BL; MicroRNAs; Naltrexone; Narcotic Antagonists; Receptors, Neurokinin-1; RNA Interference | 2010 |
Extended-release naltrexone for treatment of alcohol dependence in primary care.
Topics: Adult; Alcohol Drinking; Alcoholism; Cohort Studies; Delayed-Action Preparations; Female; Hospitals, Public; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Satisfaction; Primary Health Care | 2010 |
Pharmacologic dissociation between impulsivity and alcohol drinking in high alcohol preferring mice.
Topics: Alcohol Drinking; Alcoholism; Amphetamine; Animals; Behavior, Addictive; Choice Behavior; Female; Impulsive Behavior; Male; Memantine; Mice; Naltrexone; Reaction Time | 2010 |
Dual efficacy of delta opioid receptor-selective ligands for ethanol drinking and anxiety.
Topics: Alcohol Deterrents; Alcohol Drinking; Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Benzamides; Diazepam; Ligands; Mice; Mice, Inbred C57BL; Mice, Knockout; Naltrexone; Narcotic Antagonists; Piperazines; Quinolines; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Opioid, delta; Substance Withdrawal Syndrome | 2010 |
Region-specific induction of FosB/ΔFosB by voluntary alcohol intake: effects of naltrexone.
Topics: Alcohol Drinking; Animals; Corpus Striatum; Drug Interactions; Naltrexone; Narcotic Antagonists; Prefrontal Cortex; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Up-Regulation | 2010 |
Percentage of subjects with no heavy drinking days: evaluation as an efficacy endpoint for alcohol clinical trials.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Female; Fructose; Humans; Male; Naltrexone; Randomized Controlled Trials as Topic; Taurine; Temperance; Time Factors; Topiramate; Treatment Outcome | 2010 |
Assessment of GABA-B, metabotropic glutamate, and opioid receptor involvement in an animal model of binge drinking.
Topics: Alcohol Drinking; Animals; Baclofen; Disease Models, Animal; Ethanol; Excitatory Amino Acid Antagonists; GABA-B Receptor Agonists; Male; Mice; Mice, Inbred C57BL; Naltrexone; Narcotic Antagonists; Pyridines; Receptors, GABA-B; Receptors, Metabotropic Glutamate; Receptors, Opioid; Self Administration; Sucrose | 2011 |
Changes in the expression of transthyretin and protein kinase Cγ genes in the prefrontal cortex in response to naltrexone.
Topics: Alcohol Drinking; Animals; Gene Expression; Hippocampus; Male; Mice; Mice, Inbred C57BL; Naltrexone; Narcotic Antagonists; Oligonucleotide Array Sequence Analysis; Prealbumin; Prefrontal Cortex; Protein Kinase C; Reverse Transcriptase Polymerase Chain Reaction | 2011 |
The response to naltrexone in ethanol-drinking rats depends on early environmental experiences.
Topics: Alcohol Drinking; Animals; Central Nervous System Depressants; Dose-Response Relationship, Drug; Drinking; Environment; Ethanol; Naltrexone; Narcotic Antagonists; Rats; Rats, Wistar | 2011 |
Preliminary evaluation of extended-release naltrexone in Michigan and Missouri drug courts.
Topics: Adult; Alcohol Drinking; Alcoholism; Automobile Driving; Criminal Law; Delayed-Action Preparations; Female; Humans; Injections, Intramuscular; Male; Michigan; Missouri; Naltrexone; Narcotic Antagonists; Pilot Projects; Retrospective Studies; Substance Abuse Detection; Substance Withdrawal Syndrome; Temperance | 2011 |
Open-label pilot study of extended-release naltrexone to reduce drinking and driving among repeat offenders.
Topics: Adult; Alcohol Drinking; Alcoholism; Automobile Driving; Biomarkers; Breath Tests; Criminals; Delayed-Action Preparations; Feasibility Studies; Female; Humans; Injections, Intravenous; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Pilot Projects; Protective Devices; Recurrence; Treatment Outcome; Young Adult | 2011 |
Opioidergic modulation of ethanol self-administration in the ventral pallidum.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Alcohol Drinking; Analgesics, Opioid; Animals; Dose-Response Relationship, Drug; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Enkephalin, D-Penicillamine (2,5)-; Globus Pallidus; Male; Microinjections; Morphine; Motor Activity; Naltrexone; Narcotic Antagonists; Rats; Receptors, Opioid; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu; Self Administration; Somatostatin | 2012 |
Effects of naltrexone and LY255582 on ethanol maintenance, seeking, and relapse responding by alcohol-preferring (P) rats.
Topics: Alcohol Drinking; Animals; Central Nervous System Depressants; Conditioning, Operant; Cyclohexanes; Drug-Seeking Behavior; Ethanol; Extinction, Psychological; Female; Naltrexone; Narcotic Antagonists; Piperidines; Rats; Secondary Prevention | 2012 |
Effects of oral loperamide on efficacy of naltrexone, baclofen and AM-251 in blocking ethanol self-administration in rats.
Topics: Administration, Oral; Alcohol Deterrents; Alcohol Drinking; Animals; Animals, Outbred Strains; Baclofen; Behavior, Animal; Drug Synergism; Drug Therapy, Combination; GABA-B Receptor Agonists; Loperamide; Male; Naltrexone; Narcotic Antagonists; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Receptors, Opioid, kappa; Receptors, Opioid, mu | 2012 |
Early maternal separation affects ethanol-induced conditioning in a nor-BNI insensitive manner, but does not alter ethanol-induced locomotor activity.
Topics: Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Animals, Newborn; Appetitive Behavior; Behavior, Animal; Conditioning, Psychological; Dose-Response Relationship, Drug; Exploratory Behavior; Female; Male; Maternal Deprivation; Motor Activity; Naltrexone; Narcotic Antagonists; Random Allocation; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Reinforcement, Psychology; Severity of Illness Index | 2012 |
Ethanol drinking-in-the-dark facilitates behavioral sensitization to ethanol in C57BL/6J, BALB/cByJ, but not in mu-opioid receptor deficient CXBK mice.
Topics: Alcohol Drinking; Animals; Behavior, Animal; Blotting, Western; Brain Chemistry; Central Nervous System Depressants; Darkness; Ethanol; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Motor Activity; Naltrexone; Narcotic Antagonists; Neuronal Plasticity; Receptors, Opioid, mu; Species Specificity | 2012 |
A mixed non-homogeneous hidden Markov model for categorical data, with application to alcohol consumption.
Topics: Alcohol Drinking; Algorithms; Clinical Trials as Topic; Computer Simulation; Humans; Longitudinal Studies; Markov Chains; Models, Statistical; Naltrexone; Narcotic Antagonists | 2012 |
Effects of naltrexone on alcohol drinking patterns and extinction of alcohol seeking in baboons.
Topics: Alcohol Drinking; Animals; Cues; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Seeking Behavior; Ethanol; Extinction, Psychological; Male; Motivation; Naltrexone; Narcotic Antagonists; Papio; Reinforcement Schedule; Self Administration | 2012 |
δ-opioid receptor function in the dorsal striatum plays a role in high levels of ethanol consumption in rats.
Topics: Age Factors; Alcohol Drinking; Analgesia; Animals; Corpus Striatum; Drug Synergism; Ethanol; Guanosine 5'-O-(3-Thiotriphosphate); Male; Microinjections; Naltrexone; Quinolines; Radioligand Assay; Rats; Rats, Long-Evans; Receptors, Opioid, delta; Sulfur Radioisotopes | 2012 |
Cocaine reverses the naltrexone-induced reduction in operant ethanol self-administration: the effects on immediate-early gene expression in the rat prefrontal cortex.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Animals; Carrier Proteins; Cocaine; Conditioning, Operant; Cyclooxygenase 2; Dose-Response Relationship, Drug; Gene Expression; Genes, fos; Genes, Immediate-Early; Homer Scaffolding Proteins; Male; Motor Activity; Naltrexone; Narcotic Antagonists; Prefrontal Cortex; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; Self Administration; Taurine | 2012 |
The monoamine stabilizer (-)-OSU6162 attenuates voluntary ethanol intake and ethanol-induced dopamine output in nucleus accumbens.
Topics: Alcohol Drinking; Animals; Behavioral Symptoms; Cues; Disease Models, Animal; Dopamine; Drug Discovery; Ethanol; Male; Microdialysis; Naltrexone; Narcotic Antagonists; Nucleus Accumbens; Piperidines; Rats; Reward; Secondary Prevention; Substance Withdrawal Syndrome | 2012 |
[Between cider and cirrhosis].
Topics: Alcohol Deterrents; Alcohol Drinking; Humans; Liver Cirrhosis; Magnesium Deficiency; Naltrexone; Proton Pump Inhibitors | 2012 |
Pharmacological characterization of the 20% alcohol intermittent access model in Sardinian alcohol-preferring rats: a model of binge-like drinking.
Topics: Alcohol Drinking; Animals; Benzazepines; Binge Drinking; Choice Behavior; Disease Models, Animal; Dopamine Antagonists; Ethanol; Male; Naltrexone; Narcotic Antagonists; Pyrimidines; Rats; Receptors, Corticotropin-Releasing Hormone; Self Administration | 2013 |
Specific and nonspecific effects of naltrexone on goal-directed and habitual models of alcohol seeking and drinking.
Topics: Alcohol Drinking; Animals; Behavior, Addictive; Conditioning, Operant; Disease Models, Animal; Ethanol; Goals; Male; Naltrexone; Rats; Rats, Long-Evans; Self Administration; Sucrose | 2013 |
Effect of selective blockade of mu(1) or delta opioid receptors on reinstatement of alcohol-seeking behavior by drug-associated stimuli in rats.
Topics: Alcohol Drinking; Analysis of Variance; Animals; Central Nervous System Depressants; Cues; Discrimination, Psychological; Ethanol; Extinction, Psychological; Male; Naloxone; Naltrexone; Narcotic Antagonists; Rats; Rats, Wistar; Receptors, Opioid, delta; Receptors, Opioid, mu; Reinforcement, Psychology; Self Administration | 2002 |
Effect of naltrexone on oral consumption of concurrently available ethanol and cocaine in the rat.
Topics: Administration, Oral; Alcohol Drinking; Animals; Behavior, Addictive; Cocaine; Dose-Response Relationship, Drug; Ethanol; Male; Naltrexone; Rats; Rats, Wistar | 2002 |
Cue-induced behavioural activation: a novel model of alcohol craving?
Topics: Alcohol Drinking; Animals; Behavior, Addictive; Cues; Discrimination Learning; Environment; Ethanol; Male; Models, Psychological; Naltrexone; Narcotic Antagonists; Rats; Rats, Wistar; Reinforcement, Psychology; Self Administration; Time Factors | 2003 |
Effects of naltrexone alone and in combination with acamprosate on the alcohol deprivation effect in rats.
Topics: Acamprosate; Alcohol Drinking; Animals; Behavior, Addictive; Conditioning, Operant; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ethanol; Male; Naltrexone; Rats; Rats, Wistar; Taurine; Temperance | 2003 |
Combined low dose treatment with opioid and cannabinoid receptor antagonists synergistically reduces the motivation to consume alcohol in rats.
Topics: Alcohol Drinking; Animals; Cannabinoids; Dose-Response Relationship, Drug; Drug Combinations; Drug Synergism; Male; Motivation; Naloxone; Naltrexone; Narcotic Antagonists; Piperidines; Pyrazoles; Rats; Rats, Wistar; Rimonabant | 2004 |
Effect of the combination of naltrexone and acamprosate on alcohol intake in mice.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Dose-Response Relationship, Drug; Drug Therapy, Combination; Male; Mice; Mice, Inbred C57BL; Naltrexone; Narcotic Antagonists; Taurine | 2004 |
Noncontingent and response-contingent intravenous ethanol attenuates the effect of naltrexone on hypothalamic-pituitary-adrenal activity in rhesus monkeys.
Topics: Adrenocorticotropic Hormone; Alcohol Drinking; Animals; Dose-Response Relationship, Drug; Ethanol; Female; Hypothalamo-Hypophyseal System; Infusions, Intravenous; Macaca mulatta; Male; Naltrexone; Pituitary-Adrenal System | 2004 |
5-HT3 antagonist ICS 205-930 enhances naltrexone's effects on ethanol intake.
Topics: Alcohol Drinking; Animals; Dose-Response Relationship, Drug; Drug Synergism; Ethanol; Indoles; Male; Naltrexone; Rats; Rats, Sprague-Dawley; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Tropisetron | 2004 |
Using daily interactive voice response technology to measure drinking and related behaviors in a pharmacotherapy study.
Topics: Adult; Alcohol Drinking; Female; Humans; Interviews as Topic; Linear Models; Male; Middle Aged; Naltrexone; Patient Compliance; Pilot Projects; Statistics, Nonparametric; Voice | 2004 |
[Validation study of the Multidimensional Alcohol Craving Scale (MACS)].
Topics: Adult; Alcohol Drinking; Compulsive Behavior; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Prospective Studies; Psychiatric Status Rating Scales; Reproducibility of Results; Surveys and Questionnaires | 2004 |
The effect of baclofen alone and in combination with naltrexone on ethanol consumption in the rat.
Topics: Alcohol Drinking; Animals; Baclofen; Dose-Response Relationship, Drug; GABA Agonists; Male; Naltrexone; Narcotic Antagonists; Rats; Rats, Wistar | 2004 |
The mosaic of addiction.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior, Addictive; Disease Models, Animal; Endorphins; Ethanol; Euphoria; Humans; Naltrexone; Receptors, Dopamine D2; Receptors, Opioid; Secondary Prevention; Taurine | 2004 |
Ask the doctor. I need to quit drinking, but don't think I can do it on my own. Can I use a drug like Antabuse even though I have heart disease?
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Contraindications; Disulfiram; Heart Diseases; Humans; Naltrexone; Taurine | 2004 |
Ethanol palatability and consumption by high ethanol-drinking rats: manipulation of the opioid system with naltrexone.
Topics: Alcohol Drinking; Animals; Dose-Response Relationship, Drug; Ethanol; Male; Naltrexone; Narcotic Antagonists; Rats; Receptors, Opioid | 2004 |
Effect of the combination of naltrexone and baclofen, on acquisition of alcohol drinking behavior in alcohol-preferring rats.
Topics: Alcohol Drinking; Animals; Baclofen; Drug Therapy, Combination; Male; Naltrexone; Rats | 2005 |
Correlation of stable elevations in striatal mu-opioid receptor availability in detoxified alcoholic patients with alcohol craving: a positron emission tomography study using carbon 11-labeled carfentanil.
Topics: Adult; Alcohol Drinking; Alcoholism; Basal Ganglia; Behavior, Addictive; Carbon Radioisotopes; Fentanyl; Hospitalization; Humans; Male; Naltrexone; Narcotic Antagonists; Positron-Emission Tomography; Psychiatric Status Rating Scales; Receptors, Opioid, mu; Severity of Illness Index; Temperance | 2005 |
A single injection of the kappa opioid antagonist norbinaltorphimine increases ethanol consumption in rats.
Topics: Alcohol Drinking; Animals; Body Weight; Choice Behavior; Conditioning, Psychological; Drinking; Female; Male; Naltrexone; Rats; Rats, Inbred Lew; Receptors, Opioid, kappa; Sex Characteristics | 2005 |
Reduction of ethanol intake by chronic treatment with Hypericum perforatum, alone or combined with naltrexone in rats.
Topics: Administration, Oral; Alcohol Drinking; Animals; Bridged Bicyclo Compounds; Dose-Response Relationship, Drug; Drinking; Eating; Hypericum; Injections, Intraperitoneal; Male; Naltrexone; Narcotic Antagonists; Phloroglucinol; Plant Extracts; Rats; Terpenes; Time Factors; Treatment Outcome | 2005 |
The ethanol self-administration context as a reinstatement cue: acute effects of naltrexone.
Topics: Alcohol Drinking; Animals; Association Learning; Central Nervous System Depressants; Ethanol; Extinction, Psychological; Male; Naltrexone; Narcotic Antagonists; Rats; Rats, Long-Evans; Recurrence; Self Administration; Sweetening Agents | 2006 |
Buprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor system.
Topics: Alcohol Drinking; Analysis of Variance; Animals; Behavior, Animal; Buprenorphine; Disease Models, Animal; Dose-Response Relationship, Drug; Drinking; Drinking Behavior; Drug Administration Routes; Drug Interactions; Eating; Ethanol; Exploratory Behavior; Male; Naltrexone; Narcotic Antagonists; Nociceptin; Nociceptin Receptor; Opioid Peptides; Rats; Receptors, Opioid; Receptors, Opioid, mu; Time Factors | 2007 |
Ethanol familiarity and naltrexone treatment affect ethanol responses in rats.
Topics: Alcohol Deterrents; Alcohol Drinking; Animals; Avoidance Learning; Ethanol; Habituation, Psychophysiologic; Male; Naltrexone; Narcotic Antagonists; Rats; Rats, Long-Evans; Taste | 2005 |
Schedule-induced alcohol drinking: non-selective effects of acamprosate and naltrexone.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Appetitive Behavior; Dose-Response Relationship, Drug; Drinking; Hunger; Injections, Intraperitoneal; Male; Mice; Mice, Inbred Strains; Naltrexone; Reinforcement Schedule; Taurine; Thirst | 2006 |
[Maintaining abstinence after alcohol detoxification].
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Ambulatory Care; Behavior Therapy; Clinical Protocols; Cognitive Behavioral Therapy; Disulfiram; Follow-Up Studies; Humans; Naltrexone; Patient Care Planning; Psychoanalytic Therapy; Psychotherapy, Group; Psychotropic Drugs; Social Support; Taurine; Temperance | 2006 |
The nociceptin/orphanin FQ receptor agonist Ro 64-6198 reduces alcohol self-administration and prevents relapse-like alcohol drinking.
Topics: Alcohol Drinking; Alcohols; Animals; Behavior, Animal; Conditioning, Operant; Dose-Response Relationship, Drug; Drug Interactions; Imidazoles; Male; Naltrexone; Narcotic Antagonists; Nociceptin Receptor; Rats; Rats, Wistar; Receptors, Opioid; Saccharin; Self Administration; Spiro Compounds; Sweetening Agents | 2007 |
Effect of acute administration of ethanol on beta-endorphin plasma level in ethanol preferring and non-preferring rats chronically treated with naltrexone.
Topics: Alcohol Drinking; Animals; beta-Endorphin; Ethanol; Naltrexone; Narcotic Antagonists; Rats | 2006 |
Dissociation between opioid and CRF1 antagonist sensitive drinking in Sardinian alcohol-preferring rats.
Topics: Alcohol Drinking; Animals; Behavior, Addictive; Central Nervous System Agents; Drinking; Ethanol; Male; Naltrexone; Narcotic Antagonists; Pyrimidines; Pyrroles; Rats; Rats, Inbred Strains; Receptors, Corticotropin-Releasing Hormone; Reinforcement, Psychology; Self Administration; Stress, Psychological; Triazines | 2006 |
Gene transcription alterations associated with decrease of ethanol intake induced by naltrexone in the brain of Wistar rats.
Topics: Alcohol Drinking; Analgesics, Opioid; Animals; Autoradiography; Brain Chemistry; Central Nervous System Depressants; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Ethanol; Guanosine 5'-O-(3-Thiotriphosphate); Image Processing, Computer-Assisted; In Situ Hybridization; Male; Naltrexone; Narcotic Antagonists; Rats; Rats, Wistar; Transcription, Genetic | 2007 |
Distinct patterns of neural activation associated with ethanol seeking: effects of naltrexone.
Topics: Alcohol Drinking; Analysis of Variance; Animals; Behavior, Addictive; Behavior, Animal; Brain; Central Nervous System Depressants; Conditioning, Operant; Cues; Disease Models, Animal; Ethanol; Gene Expression Regulation; Male; Naltrexone; Narcotic Antagonists; Oncogene Proteins v-fos; Rats; Rats, Wistar; Reaction Time | 2007 |
Effects of atypical anxiolytic N-phenyl-2-[1-[3-(2-pyridinylethynyl)benzoyl]-4-piperidine]acetamide (JNJ-5234801) on alcohol intake in alcohol-preferring P rats.
Topics: Acute Disease; Alcohol Drinking; Animals; Anti-Anxiety Agents; Chronic Disease; Dose-Response Relationship, Drug; Drinking; Drug Tolerance; Injections, Intraperitoneal; Male; Naltrexone; Narcotic Antagonists; Piperidines; Pyridines; Rats | 2007 |
Alcohol consumption is enhanced after naltrexone treatment.
Topics: Alcohol Drinking; Animals; Body Weight; Drinking; Eating; Male; Naltrexone; Narcotic Antagonists; Rats; Rats, Inbred WF; Receptors, Opioid | 2007 |
Acute effects of naltrexone and GBR 12909 on ethanol drinking-in-the-dark in C57BL/6J mice.
Topics: Alcohol Drinking; Alcoholic Intoxication; Animals; Behavior, Animal; Central Nervous System Depressants; Darkness; Disease Models, Animal; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drinking Behavior; Ethanol; Injections, Intraperitoneal; Male; Mice; Mice, Inbred C57BL; Naltrexone; Narcotic Antagonists; Piperazines; Reproducibility of Results; Self Administration; Signal Transduction | 2007 |
Family history of alcoholism influences naltrexone-induced reduction in alcohol drinking.
Topics: Adult; Alcohol Drinking; Alcoholism; Behavior, Addictive; Choice Behavior; Dose-Response Relationship, Drug; Family; Female; Genetic Predisposition to Disease; Humans; Male; Naltrexone; Narcotic Antagonists; Reward; Sex Factors; Treatment Outcome | 2007 |
14-Methoxymetopon, a highly potent mu opioid agonist, biphasically affects ethanol intake in Sardinian alcohol-preferring rats.
Topics: Alcohol Drinking; Analgesics, Opioid; Animals; Dose-Response Relationship, Drug; Ethanol; Male; Morphine Derivatives; Naltrexone; Narcotic Antagonists; Rats; Rats, Inbred Strains; Receptors, Opioid, mu; Reinforcement, Psychology; Self Administration | 2007 |
Resistance to change of alcohol self-administration: effects of alcohol-delivery rate on disruption by extinction and naltrexone.
Topics: Alcohol Drinking; Animals; Behavior, Animal; Central Nervous System Depressants; Conditioning, Operant; Ethanol; Extinction, Psychological; Male; Naltrexone; Narcotic Antagonists; Rats; Rats, Long-Evans; Reinforcement Schedule; Self Administration | 2007 |
Evidence for the role of dopamine D3 receptors in oral operant alcohol self-administration and reinstatement of alcohol-seeking behavior in mice.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Conditioning, Operant; Dose-Response Relationship, Drug; Injections, Intraperitoneal; Male; Mice; Mice, Inbred C57BL; Naltrexone; Nitriles; Receptors, Dopamine D3; Taurine; Tetrahydroisoquinolines | 2007 |
Delta receptor antagonism, ethanol taste reactivity, and ethanol consumption in outbred male rats.
Topics: Alcohol Deterrents; Alcohol Drinking; Animals; Behavior, Animal; Central Nervous System Depressants; Dose-Response Relationship, Drug; Ethanol; Male; Naltrexone; Narcotic Antagonists; Rats; Rats, Long-Evans; Receptors, Opioid, delta; Reproducibility of Results; Self Administration; Taste | 2006 |
Moderators of naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment.
Topics: Adult; Age of Onset; Alcohol Drinking; Alcoholism; Environment; Female; Humans; Male; Minisatellite Repeats; Naltrexone; Narcotic Antagonists; Patient Compliance; Polymorphism, Single Nucleotide; Receptors, Dopamine D4; Receptors, Opioid, mu; Reproducibility of Results; Sex Factors; Time Factors | 2008 |
Voluntary alcohol consumption and plasma beta-endorphin levels in alcohol-preferring rats chronically treated with naltrexone.
Topics: Alcohol Drinking; Alcoholism; Analysis of Variance; Animals; Behavior, Animal; beta-Endorphin; Central Nervous System Depressants; Disease Models, Animal; Ethanol; Female; Naltrexone; Narcotic Antagonists; Rats; Time Factors | 2008 |
Alcohol preference in mice lacking the Avpr1a vasopressin receptor.
Topics: Alcohol Drinking; Amino Acids; Animals; Arginine Vasopressin; Central Nervous System Depressants; Dizocilpine Maleate; Ethanol; Excitatory Amino Acid Antagonists; Extracellular Space; Glutamic Acid; In Situ Hybridization; Mice; Mice, Inbred C57BL; Mice, Knockout; Naltrexone; Narcotic Antagonists; Receptors, N-Methyl-D-Aspartate; Receptors, Vasopressin; Sex Characteristics | 2008 |
Memantine enhances the inhibitory effects of naltrexone on ethanol consumption.
Topics: Alcohol Drinking; Animals; Behavior, Animal; Conditioning, Operant; Dose-Response Relationship, Drug; Drug Synergism; Ethanol; Excitatory Amino Acid Antagonists; Injections, Intraperitoneal; Male; Memantine; Models, Animal; Naltrexone; Narcotic Antagonists; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Reinforcement, Psychology; Self Administration | 2008 |
Preclinical models to evaluate potential pharmacotherapeutic agents in treating alcoholism and studying the neuropharmacological bases of ethanol-seeking behaviors in rats.
Topics: Alcohol Drinking; Alcoholism; Animals; Behavior, Addictive; Disease Models, Animal; Drug Evaluation, Preclinical; Ethanol; Female; Male; Naltrexone; Rats; Reinforcement Schedule | 2002 |
High voluntary alcohol consumption, in experimental liver cirrhosis is hardly responsive to opioid antagonist treatment.
Topics: Alcohol Drinking; Animals; Behavior, Animal; Bilirubin; Brain; Disease Models, Animal; Drinking; Liver Cirrhosis; Male; Naloxone; Naltrexone; Narcotic Antagonists; Prothrombin Time; Radioligand Assay; Rats; Rats, Wistar; Receptors, Opioid, mu; Thioacetamide; Time Factors | 2008 |
A pilot study of naltrexone and BASICS for heavy drinking young adults.
Topics: Adolescent; Adult; Alcohol Drinking; Combined Modality Therapy; Counseling; Ethanol; Female; Humans; Male; Motivation; Naltrexone; Narcotic Antagonists; Pilot Projects; Risk Factors; Students; Treatment Outcome; Young Adult | 2008 |
Suppression of ethanol consumption by MET-enkephalin in rats.
Topics: Alcohol Drinking; Animals; Depression, Chemical; Endorphins; Enkephalin, Methionine; Enkephalins; Injections, Intraventricular; Male; Naltrexone; Rats | 1982 |
Naltrexone: a clinical perspective.
Topics: Adult; Alcohol Drinking; Ambulatory Care; Follow-Up Studies; Heroin Dependence; Hospitalization; Humans; Middle Aged; Naloxone; Naltrexone; Opioid-Related Disorders; Patient Dropouts; Social Support; Substance Withdrawal Syndrome | 1984 |
Attenuation of alcohol drinking in tetrahydroisoquinoline-treated rats by morphine and naltrexone.
Topics: Alcohol Drinking; Animals; Body Weight; Drinking Behavior; Feeding Behavior; Isoquinolines; Male; Morphine; Naloxone; Naltrexone; Rats; Rats, Inbred Strains; Tetrahydroisoquinolines | 1983 |
The delta opioid receptor antagonist naltrindole attenuates both alcohol and saccharin intake in rats selectively bred for alcohol preference.
Topics: Alcohol Drinking; Animals; Drinking; Eating; Male; Naltrexone; Narcotic Antagonists; Rats; Rats, Inbred Strains; Receptors, Opioid, delta; Saccharin | 1995 |
The delta 2-opioid receptor antagonist naltriben selectively attenuates alcohol intake in rats bred for alcohol preference.
Topics: Alcohol Deterrents; Alcohol Drinking; Animals; Brain Chemistry; Male; Naltrexone; Quinine; Rats; Rats, Wistar; Receptors, Opioid, delta | 1995 |
The effects of selective blockade of delta and mu opiate receptors on ethanol consumption by C57BL/6 mice in a restricted access paradigm.
Topics: Alcohol Drinking; Animals; Mice; Mice, Inbred C57BL; Naltrexone; Narcotic Antagonists; Receptors, Opioid, delta; Receptors, Opioid, mu | 1993 |
Naltrexone persistently reduces rats' intake of a palatable alcoholic beverage.
Topics: Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Dose-Response Relationship, Drug; Male; Motivation; Naltrexone; Narcotic Antagonists; Rats; Rats, Sprague-Dawley; Taste | 1996 |
Alcohol drinking is reduced by a mu 1- but not by a delta-opioid receptor antagonist in alcohol-preferring rats.
Topics: Alcohol Drinking; Animals; Dose-Response Relationship, Drug; Drinking; Eating; Enkephalin, D-Penicillamine (2,5)-; Enkephalins; Injections, Intraperitoneal; Male; Motor Activity; Naloxone; Naltrexone; Narcotic Antagonists; Rats; Rats, Inbred Strains; Receptors, Opioid, delta; Receptors, Opioid, mu | 1996 |
Suppression of alcohol preference in high alcohol drinking rats: efficacy of amperozide versus naltrexone.
Topics: Alcohol Deterrents; Alcohol Drinking; Animals; Dose-Response Relationship, Drug; Drinking Behavior; Eating; Ethanol; Male; Naltrexone; Narcotic Antagonists; Piperazines; Rats; Rats, Inbred Strains; Serotonin Antagonists; Time Factors | 1996 |
Periodic naltrexone and propensity to take alcoholic beverage.
Topics: Alcohol Drinking; Alcoholism; Animals; Male; Motivation; Naltrexone; Narcotic Antagonists; Rats; Rats, Sprague-Dawley; Receptors, Opioid; Taste; Temperance | 1996 |
Interaction between opiate and 5-HT3 receptor antagonists in the regulation of alcohol intake.
Topics: Alcohol Drinking; Animals; Drug Synergism; Humans; Male; Mice; Mice, Inbred C57BL; Naltrexone; Narcotic Antagonists; Ondansetron; Rats; Rats, Wistar; Receptors, Serotonin; Receptors, Serotonin, 5-HT3; Serotonin Antagonists | 1994 |
Characterization of the decline in alcohol consumption by aminopeptidase inhibition.
Topics: Alcohol Drinking; Aminopeptidases; Angiotensin II; Animals; Biphenyl Compounds; Dose-Response Relationship, Drug; Drinking Behavior; Enkephalins; Imidazoles; Leucine; Losartan; Male; Naltrexone; Rats; Rats, Wistar; Tetrazoles | 1996 |
Sequential use of naltrexone in the treatment of relapsing alcoholism.
Topics: Adult; Alcohol Drinking; Alcoholism; Drug Administration Schedule; Humans; Male; Naltrexone; Recurrence | 1997 |
Naltrexone treatment increases the aversiveness of alcohol for outbred rats.
Topics: Alcohol Drinking; Animals; Avoidance Learning; Dose-Response Relationship, Drug; Male; Motivation; Naltrexone; Narcotic Antagonists; Opioid Peptides; Rats; Receptors, Opioid; Taste | 1997 |
Naltrexone blocks acquisition of voluntary ethanol intake in rats.
Topics: Alcohol Drinking; Animals; Association Learning; Avoidance Learning; Conditioning, Classical; Dose-Response Relationship, Drug; Injections, Intraperitoneal; Male; Motivation; Naltrexone; Narcotic Antagonists; Rats; Receptors, Opioid; Taste | 1997 |
Naltrexone effects on ethanol drinking acquisition and on established ethanol consumption in C57BL/6J mice.
Topics: Alcohol Drinking; Alcoholism; Animals; Brain; Dose-Response Relationship, Drug; Drug Implants; Female; Mice; Mice, Inbred C57BL; Motivation; Naltrexone; Narcotic Antagonists; Opioid Peptides; Receptors, Opioid | 1997 |
Current research in the treatment of alcoholism in liver transplant recipients.
Topics: Alcohol Drinking; Alcoholism; Double-Blind Method; Female; Humans; Liver Diseases, Alcoholic; Liver Transplantation; Male; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Recurrence; Research Design | 1997 |
Combination of naltrexone and fluoxetine on rats' propensity to take alcoholic beverage.
Topics: Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Dose-Response Relationship, Drug; Drug Synergism; Drug Tolerance; Fluoxetine; Male; Naltrexone; Narcotic Antagonists; Rats; Rats, Sprague-Dawley; Receptors, Opioid; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors | 1997 |
A preliminary investigation of the management of alcohol dependence with naltrexone by primary care providers.
Topics: Alcohol Drinking; Alcoholism; Counseling; Female; Humans; Liver; Male; Naltrexone; Narcotic Antagonists; Patient Compliance; Patient Education as Topic; Patient Satisfaction; Primary Health Care; Treatment Outcome | 1997 |
Isradipine and naltrexone in combination with isradipine interact with a period of abstinence to reduce rats' intakes of an alcoholic beverage.
Topics: Alcohol Drinking; Alcoholic Beverages; Animals; Behavior, Animal; Body Weight; Dose-Response Relationship, Drug; Ethanol; Isradipine; Male; Naltrexone; Rats; Rats, Sprague-Dawley; Self Administration | 1997 |
Effect of mu opioid receptor blockade on alcohol intake in rats bred for high alcohol drinking.
Topics: Alcohol Drinking; Animals; Autoradiography; Gene Expression Regulation; Male; Naltrexone; Narcotic Antagonists; Pituitary Gland; Pro-Opiomelanocortin; Rats; Rats, Inbred Strains; Receptors, Opioid, mu; RNA, Messenger | 1998 |
Brain opioid receptor binding of [3H]CTOP and [3H]naltrindole in alcohol-preferring AA and alcohol-avoiding ANA rats.
Topics: Alcohol Drinking; Amygdala; Animals; Autoradiography; Brain; Corpus Striatum; Food Preferences; Hippocampus; Male; Naltrexone; Narcotic Antagonists; Rats; Rats, Mutant Strains; Receptors, Opioid; Receptors, Opioid, delta; Receptors, Opioid, mu; Somatostatin; Substantia Nigra; Tritium | 1998 |
Effects of acute and chronic doses of naltrexone on ethanol self-administration in rhesus monkeys.
Topics: Alcohol Drinking; Animals; Dose-Response Relationship, Drug; Injections, Intramuscular; Macaca mulatta; Male; Motivation; Naltrexone; Narcotic Antagonists; Premedication; Receptors, Opioid; Self Administration | 1998 |
A comparison of the effects of the opioid antagonists naltrexone, naltrindole, and beta-funaltrexamine on ethanol consumption in the rat.
Topics: Alcohol Drinking; Animals; Male; Naltrexone; Narcotic Antagonists; Rats; Rats, Wistar; Receptors, Opioid, delta; Receptors, Opioid, mu | 1998 |
Naltrexone and amperozide modify chocolate and saccharin drinking in high alcohol-preferring P rats.
Topics: Alcohol Drinking; Animals; Body Weight; Cacao; Dose-Response Relationship, Drug; Eating; Male; Naltrexone; Narcotic Antagonists; Piperazines; Rats; Rats, Inbred Strains; Saccharin; Serotonin Antagonists; Sweetening Agents; Taste | 1998 |
Contribution of the opioid system to alcohol aversion and alcohol drinking behavior.
Topics: Alcohol Drinking; Animals; Conditioning, Psychological; Dose-Response Relationship, Drug; Endorphins; Enkephalins; Ethanol; Female; Naltrexone; Rats; Rats, Wistar; Receptors, Opioid, delta | 1998 |
Naltrexone reduces ethanol- and sucrose-reinforced responding in rhesus monkeys.
Topics: Administration, Oral; Alcohol Deterrents; Alcohol Drinking; Animals; Conditioning, Operant; Dose-Response Relationship, Drug; Ethanol; Female; Infusions, Intravenous; Macaca mulatta; Male; Naltrexone; Reinforcement, Psychology; Self Administration; Sucrose | 1998 |
Oral ethanol-reinforced responding in rhesus monkeys: effects of opioid antagonists selective for the mu-, kappa-, or delta-receptor.
Topics: Alcohol Drinking; Animals; Brain; Macaca mulatta; Male; Motivation; Naltrexone; Narcotic Antagonists; Opioid Peptides; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu | 1998 |
The opioid receptor antagonist nalmefene reduces responding maintained by ethanol presentation: preclinical studies in ethanol-preferring and outbred Wistar rats.
Topics: Alcohol Drinking; Alcoholism; Animals; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Genotype; Male; Motivation; Naltrexone; Narcotic Antagonists; Rats; Rats, Inbred Strains | 1998 |
Reinstatement of alcohol-seeking behavior by drug-associated discriminative stimuli after prolonged extinction in the rat.
Topics: Acoustic Stimulation; Alcohol Drinking; Animals; Discrimination Learning; Discrimination, Psychological; Extinction, Psychological; Male; Naltrexone; Narcotic Antagonists; Rats; Rats, Wistar; Self Administration | 1999 |
Bremazocine reduces unrestricted free-choice ethanol self-administration in rats without affecting sucrose preference.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Alcohol Drinking; Alcoholism; Animals; Benzomorphans; Ethanol; Male; Motor Activity; Naltrexone; Narcotic Antagonists; Rats; Rats, Wistar; Receptors, Opioid; Reinforcement, Psychology; Self Administration; Sucrose | 1999 |
Conditioned effects produced by naltrexone doses that reduce ethanol-reinforced responding in rhesus monkeys.
Topics: Alcohol Drinking; Animals; Avoidance Learning; Behavior, Animal; Conditioning, Classical; Conditioning, Operant; Drinking Behavior; Ethanol; Macaca mulatta; Male; Naltrexone; Reward; Sodium Chloride; Taste | 1999 |
Ethanol consumption by Fawn-Hooded rats following abstinence: effect of naltrexone and changes in mu-opioid receptor density.
Topics: Alcohol Drinking; Animals; Binding Sites; Central Nervous System Depressants; D-Ala(2),MePhe(4),Met(0)-ol-enkephalin; Ethanol; Male; Naltrexone; Narcotic Antagonists; Prosencephalon; Rats; Receptors, Opioid, mu; Temperance | 1999 |
Ethanol-reinforced behaviour in the rat: effects of naltrexone.
Topics: Alcohol Drinking; Analysis of Variance; Animals; Behavior, Animal; Central Nervous System Depressants; Conditioning, Operant; Ethanol; Extinction, Psychological; Male; Naltrexone; Narcotic Antagonists; Rats; Rats, Wistar; Reinforcement, Psychology; Self Administration; Water | 1999 |
Quadazocine decreases responding reinforced by ethanol, sucrose, and phencyclidine fluid deliveries in rhesus monkeys: comparison to naltrexone's effects.
Topics: Alcohol Drinking; Animals; Azocines; Central Nervous System Depressants; Drinking Behavior; Ethanol; Excitatory Amino Acid Antagonists; Female; Macaca mulatta; Male; Naltrexone; Narcotic Antagonists; Phencyclidine; Receptors, Opioid; Reinforcement, Psychology; Self Administration; Sucrose | 1999 |
Occurrence and management of depression in the context of naltrexone treatment of alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Comorbidity; Depressive Disorder; Diagnosis, Dual (Psychiatry); Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluoxetine; Humans; Middle Aged; Naltrexone; Narcotic Antagonists; Selective Serotonin Reuptake Inhibitors; Taurine | 1999 |
Effects of naltrexone and fluoxetine on alcohol self-administration and reinstatement of alcohol seeking induced by priming injections of alcohol and exposure to stress.
Topics: Alcohol Deterrents; Alcohol Drinking; Animals; Central Nervous System Depressants; Ethanol; Fluoxetine; Male; Naltrexone; Narcotic Antagonists; Rats; Self Administration; Stress, Physiological | 1999 |
The delta 2-opioid receptor antagonist naltriben reduces motivated responding for ethanol.
Topics: Alcohol Deterrents; Alcohol Drinking; Animals; Central Nervous System Depressants; Conditioning, Operant; Ethanol; Female; Motivation; Naloxone; Naltrexone; Narcotic Antagonists; Rats; Rats, Inbred Strains; Receptors, Opioid, delta; Reinforcement Schedule | 1999 |
Combination pharmacotherapy: a mixture of small doses of naltrexone, fluoxetine, and a thyrotropin-releasing hormone analogue reduces alcohol intake in three strains of alcohol-preferring rats.
Topics: Alcohol Drinking; Animals; Drug Therapy, Combination; Fluoxetine; Naltrexone; Narcotic Antagonists; Nootropic Agents; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Thyrotropin-Releasing Hormone | 2000 |
6-beta-naltrexol reduces alcohol consumption in rats.
Topics: Alcohol Drinking; Animals; Ethanol; Injections, Intraperitoneal; Male; Models, Animal; Naltrexone; Narcotic Antagonists; Placebos; Rats; Rats, Wistar | 2000 |
Reduction of alcohol drinking and upregulation of opioid receptors by oral naltrexone in AA rats.
Topics: Administration, Oral; Alcohol Drinking; Animals; Male; Naltrexone; Narcotic Antagonists; Rats; Receptors, Opioid; Up-Regulation | 2000 |
Effect of naltrexone on acute tolerance to ethanol in UChB rats.
Topics: Alcohol Drinking; Animals; Central Nervous System Depressants; Drug Tolerance; Ethanol; Female; Motor Skills; Naltrexone; Narcotic Antagonists; Rats | 2000 |
The effect of antagonists selective for mu- and delta-opioid receptor subtypes on alcohol consumption in C57BL/6 mice.
Topics: Alcohol Drinking; Animals; Male; Mice; Mice, Inbred C57BL; Naltrexone; Narcotic Antagonists; Receptors, Opioid, delta; Receptors, Opioid, mu; Somatostatin | 2000 |
Naltrexone and alcohol drinking in mice lacking beta-endorphin by site-directed mutagenesis.
Topics: Alcohol Drinking; Animals; beta-Endorphin; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Mutagenesis, Site-Directed; Naltrexone; Narcotic Antagonists | 2000 |
The selective kappa-opioid receptor agonist U50,488H attenuates voluntary ethanol intake in the rat.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Alcohol Drinking; Animals; Central Nervous System Depressants; Depression, Chemical; Drinking; Ethanol; Male; Naltrexone; Narcotic Antagonists; Rats; Rats, Inbred Lew; Receptors, Opioid, kappa | 2001 |
Suppression of ethanol responding by centrally administered CTOP and naltrindole in AA and Wistar rats.
Topics: Alcohol Drinking; Amygdala; Animals; Central Nervous System Depressants; Conditioning, Operant; Ethanol; Genotype; Male; Naloxone; Naltrexone; Narcotic Antagonists; Nucleus Accumbens; Rats; Rats, Wistar; Receptors, Opioid, delta; Receptors, Opioid, mu; Reinforcement, Psychology; Self Administration; Somatostatin | 2001 |
Kappa-opioid receptors and relapse-like drinking in long-term ethanol-experienced rats.
Topics: Alcohol Drinking; Animals; Benzofurans; Conditioning, Operant; Drinking; Eating; Male; Naltrexone; Pyrrolidines; Rats; Rats, Wistar; Receptors, Opioid, kappa; Recurrence; Self Administration | 2000 |
Effect of acamprosate and naltrexone, alone or in combination, on ethanol consumption.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Animals; Male; Naltrexone; Narcotic Antagonists; Rats; Rats, Wistar; Taurine | 2001 |
Research with rats germane to medication for alcoholism: consequences of noncompliance.
Topics: Alcohol Drinking; Alcoholism; Animals; Calcium Channel Blockers; Drinking; Drug Therapy, Combination; Isradipine; Naltrexone; Narcotic Antagonists; Rats; Rats, Sprague-Dawley; Temperance | 2001 |
Effects of naltrexone on the intake of ethanol and flavored solutions in rats.
Topics: Alcohol Drinking; Animals; Beverages; Drinking; Drug Combinations; Ethanol; Male; Naltrexone; Narcotic Antagonists; Quinine; Rats; Rats, Long-Evans; Rats, Wistar; Saccharin; Solutions | 2001 |
Interaction of morphine and naltrexone on oral ethanol self-administration in rhesus monkeys.
Topics: Alcohol Drinking; Analgesics, Opioid; Animals; Conditioning, Operant; Dose-Response Relationship, Drug; Drug Interactions; Macaca mulatta; Male; Morphine; Naltrexone; Narcotic Antagonists; Receptors, Opioid, mu; Reinforcement, Psychology | 2001 |
A comparison of the effects of 6-beta naltrexol and naltrexone on the consumption of ethanol or sucrose using a limited-access procedure in rats.
Topics: Alcohol Drinking; Animals; Dose-Response Relationship, Drug; Ethanol; Male; Naltrexone; Rats; Rats, Wistar; Sucrose | 2002 |
Low doses of naltrexone reduce palatability and consumption of ethanol in outbred rats.
Topics: Alcohol Drinking; Animals; Dose-Response Relationship, Drug; Ethanol; Male; Naltrexone; Narcotic Antagonists; Rats; Rats, Long-Evans; Taste | 2002 |
Naltrexone modifies the palatability of basic tastes and alcohol in outbred male rats.
Topics: Alcohol Drinking; Animals; Dose-Response Relationship, Drug; Drinking; Male; Naltrexone; Quinine; Rats; Rats, Long-Evans; Sodium Chloride; Sucrose; Taste | 2002 |
Ethanol preference in the hamster: effects of morphine sulfate and naltrexone, a long-acting morphine antagonist.
Topics: Alcohol Drinking; Animals; Choice Behavior; Cricetinae; Decision Making; Dextrorphan; Levorphanol; Morphine; Naloxone; Naltrexone; Time Factors | 1976 |
Interactions of narcotics, narcotic antagonists, and ethanol during acute, chronic, and withdrawal states.
Topics: Alcohol Drinking; Animals; Animals, Newborn; Dextrorphan; Drug Interactions; Ethanol; Humans; Levorphanol; Male; Methadone; Methadyl Acetate; Mice; Mice, Inbred C57BL; Morphine; Naloxone; Naltrexone; Narcotic Antagonists; Narcotics; Rats; Substance Withdrawal Syndrome; Substance-Related Disorders; Time Factors | 1976 |
Opioid modulation of alcohol intake in monkeys by low doses of naltrexone and morphine.
Topics: Alcohol Drinking; Animals; Dose-Response Relationship, Drug; Macaca mulatta; Male; Morphine; Naltrexone | 1992 |
Effect of naltrexone on alcohol consumption during chronic alcohol drinking and after a period of imposed abstinence in free-choice drinking rhesus monkeys.
Topics: Alcohol Drinking; Animals; Choice Behavior; Dose-Response Relationship, Drug; Drinking Behavior; Macaca mulatta; Male; Naltrexone; Substance Withdrawal Syndrome | 1991 |
Angiotensin converting enzyme inhibitors reduce alcohol consumption: some possible mechanisms and important conditions for its therapeutic use.
Topics: Alcohol Drinking; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Blood Pressure; Dose-Response Relationship, Drug; Drinking; Hypertension; Male; Naltrexone; Rats; Rats, Inbred Strains; Renin-Angiotensin System | 1990 |
Drugs to decrease alcohol drinking.
Topics: Alcohol Drinking; Alcoholism; Animals; Extinction, Psychological; Male; Naloxone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Rats; Rats, Inbred Strains | 1990 |
Central vs. peripheral mediation of opioid effects on alcohol consumption in free-feeding rats.
Topics: Alcohol Drinking; Animals; Dose-Response Relationship, Drug; Drinking Behavior; Drug Interactions; Loperamide; Male; Morphine; Naltrexone; Narcotic Antagonists; Piperidines; Polysorbates; Quaternary Ammonium Compounds; Rats; Rats, Inbred Strains; Time Factors | 1989 |
Opiate antagonist nalmefene inhibits ethanol-induced flushing in Asians: a preliminary study.
Topics: Acetaldehyde; Adult; Alcohol Drinking; Asian; Blood Pressure; Body Temperature Regulation; Endorphins; Ethanol; Flushing; Heart Rate; Humans; Hydrocortisone; Male; Naltrexone; Narcotic Antagonists | 1988 |
The effect of tetrahydropapaveroline and naltrexone on voluntary ethanol ingestion in rats.
Topics: Alcohol Drinking; Animals; Drug Interactions; Naltrexone; Papaverine; Rats; Rats, Inbred Strains; Reference Values; Tetrahydropapaveroline | 1988 |
Naltrexone blocks the post-shock increase of ethanol consumption.
Topics: Alcohol Drinking; Animals; Electroshock; Male; Naltrexone; Rats; Rats, Inbred Strains; Reinforcement, Psychology | 1986 |